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ABSTRACT 
Tuberculosis (TB) is an ongoing global public health crisis. In 2013, approximately 9 
million people developed active TB and 1.5 million died. This dissertation addresses high-
priority challenges in risk prediction, diagnosis and understanding bacterial adaptation to 
antibiotic exposure. An over-arching theme of this work is use of “big data” analysis to 
translate large administrative or biological datasets into novel insights into TB epidemiology.  
The first project utilized probabilistic methods to link a large overseas administrative dataset 
with US TB surveillance data. Analysis of the linked dataset provided new insights into TB 
risk among immigrants that have important implications for US guidelines. The second 
project identified blood transcriptional biomarkers for TB among US patients and 
systematically evaluated the generalizability of these biomarkers. The third and fourth 
projects evaluated how drug exposure and HIV-associated immune dysfunction alter 
transcriptional characteristics of the pathogen Mycobacterium tuberculosis (MTB) in 
patients. 
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Tuberculosis (TB) is an ongoing global public health crisis. In 2013, approximately 9 
million people developed active TB and 1.5 million died (1). This dissertation addresses 
high-priority challenges in risk prediction, diagnosis and understanding bacterial adaptation 
to antibiotic exposure. An over-arching theme of this work is use of “big data” analysis to 
translate large administrative or biological datasets into novel insights into TB epidemiology.  
The first project utilized probabilistic methods to link a large overseas administrative 
dataset with US TB surveillance data. Analysis of the linked dataset yielded new insights into 
TB risk among immigrants that have important implications for US guidelines. The second 
project identified blood transcriptional biomarkers for TB among US patients and 
systematically evaluated the generalizability of these biomarkers. The third project identified 
how drug exposure alters transcriptional characteristics of the pathogen Mycobacterium 
tuberculosis (MTB) in patients treated for TB. The final project evaluated the impact of 
human immunity on the pathogen transcriptome by comparing MTB from patients with and 
without HIV infection.  These chapter topics are introduced in greater detail below.  
Risk of reactivation of latent tuberculosis infection 
Latent TB infection (LTBI) is the central barrier to TB eradication in the United 
States (US) (2, 3). Most TB infections result in LTBI rather than active TB. LTBI is a state in 
which an individual has immunologic evidence of TB infection but is asymptomatic and non-
contagious. LTBI may remain stably contained by the immune system over the course of a 
lifetime or – depending on a patient’s clinical and epidemiologic risks – may reactivate to 





In contrast to much of the world, public health measures have largely interrupted 
transmission of TB in the US (2, 3). Currently, ~80% of TB in the US is attributable to 
reactivation of LTBI (4). For most persons with LTBI in the US, infection was acquired in 
high TB incidence countries prior to immigration. In 2014, 66.5% of TB in the US occurred 
among foreign-born persons and the rate of TB among foreign-born persons was 13.4-times 
higher than among US-born persons (5). Foreign-born persons and immigrants are therefore 
a high priority for public health prevention efforts. Importantly, an effective intervention is 
available; preventive antibiotic treatment can reduce the risk of progression from LTBI to TB 
by up to 90%. 
To effectively target LTBI screening and treatment to the populations at highest risk 
of developing TB, it is critical to understand how reactivation risk changes over time, 
especially among the foreign born. Risk of reactivation is highest within the first two years 
after infection but TB may also occur decades after initial infection. The risk of reactivation 
from LTBI to TB is modified by clinical and epidemiologic risk factors.  
A central challenge in estimating the risk of LTBI reactivation over time is that 
progression from LTBI to TB is a relatively rare event, even in immigrant populations. This 
makes it infeasible to quantify reactivation risk through a traditional cohort study of 
immigrants; the size, cost and follow-up duration is prohibitive. Estimates of LTBI 
reactivation risk among immigrants to the US has therefore been based on ecological studies.  
Ecological studies based on US surveillance data from the 1990s suggested that the 
TB rate among new arrivals to the US was >5-fold higher during the first 2-5 post-arrival 





are at high risk in the immediate post-arrival years, current US guidelines recommend LTBI 
treatment for immigrants within five years of arrival but not explicitly thereafter (9).  
A critical flaw of these ecological studies is that they do not account for the role of 
active pre- and post-immigration evaluation. For decades, applicants for US legal permanent 
residency (immigrants) have been required to undergo a pre-immigration exam and chest 
radiograph prior to departure from their home country. This pre-immigration radiographic 
screening aims to detect fibrotic scarring of the lung suggestive of TB (henceforth referred to 
as abnormal radiograph). Fibrotic scarring is a non-specific finding that may indicate the 
presence of active TB, old, healed TB that was not treated, or lung disease unrelated to TB 
(3). The subset of immigrants that have abnormal pre-immigration radiographs is required to 
undergo a post-immigration TB evaluation within months of arrival in the US (10). Post-
immigration TB evaluation often detects indolent active rather than latent TB. Importantly, 
previous ecological studies have not stratified by normal or abnormal chest radiograph, 
instead providing estimates of TB risk in the combined group. This failure to distinguish 
between immigrants with normal and abnormal chest radiographs is problematic because risk 
for post-arrival TB diagnosis likely differs between immigrants with normal and abnormal 
chest radiographs. This has important public health implications because unstratified 
ecological data are the basis of current treatment guidelines.   
In Chapter II, entitled “Persistent latent tuberculosis reactivation risk in US 
immigrants,” we employed a novel study design to estimate TB risk over time among 
immigrants. Rather than an ecological design, we used probabilistic linkage methods to 





case reports in the US. This approach enabled us to quantify TB risk over time separately 
among immigrants with normal and abnormal radiographs for the first time.  
Our data demonstrated that immigrants with normal and abnormal chest radiographs 
have very different TB risk profiles. The 86% of our immigrant cohort that had normal pre-
immigration radiographs had a relatively low rate of TB diagnosis. Contrary to assumptions 
of current treatment guidelines, risk remained constant over time. In contrast, the 14% that 
had abnormal pre-immigration radiographs had a TB rate that was initially >25-times higher 
than among immigrants with normal radiographs. Collapsing these two risk strata – 
immigrants with normal and abnormal pre-immigration radiographs – into a single group 
replicates the (misleading) findings of previous ecological studies.  
 This analysis suggests that the current US LTBI treatment guidelines are informed by 
an ecological fallacy in which inferences about risk among immigrants with normal 
radiographs are inferred (incorrectly) from ecological analysis of a population with both 
normal and abnormal chest radiographs. We found that excess risk of TB diagnosis in the 
immediate post-arrival period was borne exclusively by immigrants with abnormal 
radiographs. This is likely the result of active post-arrival TB evaluation. TB rates did not 
decline over time in immigrants with normal chest radiographs. These results suggest that 
future revisions of LTBI treatment guideline should consider extension of LTBI screening 






Blood transcriptional biomarkers for active TB 
Early, accurate diagnosis of TB is critical for control of the global TB epidemic. Early 
diagnosis not only improves the health of the individual patient being tested, but enables 
treatment that abrogates contagiousness, reducing transmission to others.  
Unfortunately, existing tests for TB have suboptimal sensitivity (11). Development of 
novel assays for TB is a leading World Health Organization priority (12). Most existing tests 
for active pulmonary TB are based on detection of the pathogen MTB in sputum. However, 
MTB is not always present in detectable levels and sputum is not always obtainable. MTB is 
rarely detectable in blood and is not found in urine. An alternative to direct pathogen 
detection is detection of host markers that are specific to TB. Since blood can be obtained 
from nearly all patients undergoing evaluation for pulmonary and/or extrapulmonary TB, a 
diagnostic test based on human markers in blood would be optimal. 
In Chapter III, entitled “Blood transcriptional biomarkers for active TB among US 
patients: A case-control study with systematic cross-classifier evaluation,” we used machine 
learning methods to evaluate patterns of mRNA expression in blood as potential biomarkers. 
The conceptual basis for this study is that specific immune responses to MTB may be 
associated with a signature mRNA pattern not seen other conditions. mRNA expression 
profiles assayed via microarray or sequencing are understood to represent a “biological 
snapshot” of adaptation to physiologic stressors.  
Several studies have previously used this approach in different populations of patients 
with TB (13-19) and have suggested blood transcriptional signatures have promise for active 
TB diagnosis. Our study differs from previous studies in several critical ways. First, our 





pneumonia. This assures practical clinical relevance to our findings; a common challenge 
encountered by health care providers is determining whether patients presenting with cough, 
fever and radiographic abnormalities have TB or pneumonia. Previously published studies 
have included comparison groups of marginal clinical relevance. Second, our study is the 
first performed in US population of diverse ancestry with a different spectrum of co-morbid 
health conditions than encountered in previously studied African populations. Third, our 
study not only identified novel transcriptional signatures for TB based on transcriptional data 
from our study subjects, but additionally performed a rigorous analysis of the generalizability 
of our and previously-published classifiers.  
We found that the accuracy and generalizability of blood transcriptional classifiers 
differed depending on the comparison group used. Our classifier distinguishing TB from 
pneumonia was accurate in our subjects. But accuracy decreased when the classifier was 
applied to new populations with other non-TB disease comparisons. By contrast, our 
classifier distinguishing TB from LTBI was highly accurate, both in our subjects and in 
previously-published data from other populations. However, this second classifier type is a 
non-specific marker for systemic illness and does not distinguish between TB and other 
diseases like pneumonia. These results led us to conclude that transcriptional classifiers may 
have potential to improve TB care and control but additional discovery and validation studies 
in diverse populations with different disease references will be required to evaluate the 
clinical usefulness of these biomarkers. 
Impact of drug treatment on M. tuberculosis transcriptome  
In Chapter IV, entitled “Transcriptional adaptation of drug-tolerant Mycobacterium 





transcriptional profiling method to elucidate changes in the MTB population that occur in 
human clinical samples during drug treatment. This project addresses a topic of the utmost 
clinical and public health importance – drug-tolerant bacterial “persister” phenotypes. Slow 
killing of drug-tolerant persisters is considered the cause of TB treatment failure and relapse 
and is the central obstacle to shorter treatment regimens (20, 21). Currently, the duration of 
the shortest standard TB treatment regimen is 6 months. This long duration is costly and 
burdensome to patients and to health systems and pre-disposes to treatment non-adherence 
which enables further transmission and acquired drug resistance (22). Understanding MTB 
persisters and developing drugs that kill drug-tolerant phenotypes is therefore a key priority.  
Isogenic drug-susceptible MTB populations are understood to include heterogeneous 
sub-populations in different phenotypic states with variable sensitivity to antibiotics. MTB 
persisters have been defined as bacterial phenotypes capable of surviving prolonged 
antibiotic exposure despite a lack of resistance-conferring genetic mutations (23).  
The clinical and epidemiologic importance of persisters in TB cannot be overstated. 
Abundant epidemiologic evidence (24-27) demonstrates that treatment results in a biphasic 
killing pattern in human TB with rapid early killing followed by slower killing. Based on this 
biphasic pattern, Mitchison and others (25, 28, 29) defined the central paradigm of TB 
chemotherapy: an initial three to five day bactericidal phase in which metabolically-active 
dividing bacilli are rapidly killed followed by a sterilizing phase in which an antibiotic-
tolerant persister subpopulation is killed more slowly. 
Many experimental models have evaluated the basis of MTB drug tolerance (24, 30-
37). However, it is unclear whether experimental models recapitulate the physiologic state of 





patterns in human clinical specimens are distinct from those observed in vitro and in murine 
models (38-40). This is important because antibiotic effectiveness depends on bacterial 
physiologic state (30, 41, 42). Until our study presented in Chapter IV, it was not technically 
feasible to characterize the transcriptional characteristics of the MTB population that 
survives prolonged antibiotic exposure.  
We found – after 14 days of drug treatment – transcriptional patterns were consistent 
with a shift in the MTB population to a slowly replicating, metabolically down-regulated 
phenotype that no longer displays signals of isoniazid-induced stress. Systematic comparison 
with transcriptional changes in previously-published experimental persister models identified 
models with greater and lesser similarity to the in vivo population. These results identify 
novel drug targets and reinforce the critical need for novel anti-TB drugs to target the 
recalcitrant drug-tolerant bacterial population, leading to more effective and shorter duration 
drug regimens.  
Impact of host immunity on M. tuberculosis transcriptome  
In Chapter V, entitled “Mycobacterium tuberculosis adaptation to impaired host 
immunity in HIV-infected patients,” we evaluated the influence of HIV-associated immune 
dysfunction on the bacterial transcriptome. HIV increases TB risk 50-100 fold. TB is the 
leading cause of death among HIV-infected people, killing an estimated 400,000 HIV-
infected persons worldwide each year (1). HIV has pervasive effects on human immunity, 
leading to strikingly different clinical presentations of TB among HIV-infected relative to 
HIV-uninfected persons, including with disseminated disease and atypical radiographic 
patterns (43). On a histologic level, HIV impairs formation of granulomas, the hallmark 





chemokine expression, changes in macrophage polarization and T cell dysfunction and 
depletion (43). Since MTB is exquisitely adapted to human immunity, dynamically adjusting 
its physiologic state to tolerate immune responses and diverse tissue micro-environmental 
conditions, (38, 44, 45) we hypothesized that these differences lead to different adaptations 
by the pathogen. Understanding how HIV alters the physiologic state of MTB in vivo is 
important because the phenotypic state of the pathogen affects antibiotic effectiveness (30, 
41, 46-48) and may affect transmission fitness (49-51). 
We therefore compared MTB transcriptional adaptation in the sputa of HIV-infected 
and HIV-uninfected patients with untreated active pulmonary TB. After a pilot study in the 
Gambia revealed that MTB in HIV-infected patients had decreased expression of DosR 
regulon genes, we confirmed this result in a larger number of Ugandan patients. To elucidate 
alterations in human immunity that drive this adaptation, we queried a panel of human genes 
associated with granuloma formation and macrophage polarization.    
We found that MTB in HIV-infected patients had decreased expression of the DosR 
regulon, a crucial metabolic switch with immunomodulatory effects. Down-regulation of 
DosR expression among HIV-infected patients may be a direct result of arginase-driven 
decreased macrophage NO production or an indirect result of decreased hypoxic stress in 
poorly formed granulomas. This analysis provides a novel perspective on the complex 
interplay between HIV-associated immune impairment, altered tissue microenvironments and 
bacterial physiologic state. 
The over-arching theme of these four projects is translation of large-scale data – 
including administrative data and high-throughput biological data – to epidemiologic 






PERSISTENT LATENT TUBERCULOSI S REACTIVATION RISK IN US 
IMMIGRANTS 1 
Introduction 
TB among foreign-born persons is a central challenge to TB elimination in the US. 
The percentage of TB cases occurring among foreign-born persons has increased steadily for 
nearly 20 years to 63% of all new US cases in 2012 (2). TB exposure is uncommon in the US 
and most TB among foreign-born persons results from reactivation of LTBI acquired prior to 
arrival (4). US policy therefore emphasizes targeted testing and treatment of LTBI after 
arrival (9, 52).  
National surveillance data in the 1990s showed TB rates >5-fold higher within five 
years of arrival compared with subsequent years (6-8). New arrivals from high incidence 
countries were hypothesized to arrive with high-risk “early latency” due to ongoing re-
exposure and reinfection with new TB strains until US arrival (53, 54). Since TB risk is 
highest immediately after infection, high TB rates immediately after arrival were assumed to 
indicate that reactivation risk declines with time in the US. US guidelines therefore target 
LTBI testing and treatment towards foreign-born persons in the US within five years of their 
arrival (9).  
An alternative explanation for high post-arrival TB rates is detection of imported TB 
disease that is already active when a person arrives in the US (55). Recent surveillance data 
indicate that TB rates are 4-6 times higher during year 1 than during years 2-4 (53, 56, 57). 
Since 1991, TB screening for adults entering to become immigrants has included a pre-
                                                 
1 This chapter was previously published as: Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, Asis 
R, Reves R. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Resp Crit Care 





immigration exam and chest radiograph at designated overseas Panel Physician Clinics. 
Immigrants with radiographic abnormalities undergo post-arrival follow-up evaluation by US 
local health agencies (10). If immigrants with abnormal radiographs are diagnosed with TB 
within six months of arrival, it is assumed TB was already active prior to arrival and their 
case is classified as imported TB (58, 59). Conversely, TB reported among immigrants 
whose pre-immigration exam was normal have been considered likely due to LTBI 
reactivation (60). TB also occurs due to post-arrival TB exposures, but the limited burden of 
ongoing TB transmission in the US makes this less common. Distinguishing LTBI 
reactivation from imported TB has important implications for LTBI treatment guidelines. 
Analyses of surveillance data have been unable to distinguish between LTBI reactivation and 
imported TB because national surveillance data prior to 2011 do not distinguish among key 
categories of new arrivals (i.e., immigrant, refugee, student, business traveler), and 
consequently, are unable to ascertain the role of pre- and post-immigration evaluation. 
The Philippines has a high TB incidence (260/100,000 in 2011) and is the source of a 
large volume of immigrants to the US (61, 62). More than 60% of Filipinos are estimated to 
have LTBI (63). Filipino immigrants have among the highest rates of TB diagnosis of any 
US immigrant group (59). In 2007, pre-immigration exam in the Philippines was enhanced to 
include sputum culture in addition to sputum microscopy to improve detection of prevalent 
TB among applicants with abnormal radiograph before departure. To evaluate reactivation 
and imported TB among a cohort of Filipinos applying for US legal permanent residency, we 
linked pre-immigration exam records with subsequently occurring cases in the California TB 






We identified a cohort of adult Filipino applicants for permanent legal residency 
intending to resettle in California and analyzed reported TB during the first 9 post-
immigration years.  
Human subjects approval 
Institutional Review Boards at the Centers for Disease Control and Prevention 
(CDC), California Department of Public Health, Denver Health and the University of Texas 
Health Sciences Center, Houston approved this study.  
Pre-immigration evaluation records  
We obtained records for visa applicants evaluated at the only pre-immigration 
screening site in the Philippines, St. Luke’s Medical Center Extension Clinic (SLMCEC), 
from January 4, 2001 to December 29, 2009. Two different screening guidelines were in 
place during this period (10). Briefly, prior to October 2007, applicants ≥15 years of age 
underwent a medical questionnaire, physical examination, and chest radiograph (1991 
guidelines). Applicants with an abnormal radiograph provided three sputum samples for acid-
fast bacilli (AFB) smears but mycobacterial culture was not performed. Applicants with 
positive smears were required to initiate TB therapy prior to clearance. Emigration was 
permitted once smears were negative. Beginning on October 1, 2007, (10) sputum specimens 
from applicants with abnormal radiographs undergo both AFB smear and mycobacterial 
culture (2007 guidelines). For applicants with positive cultures, emigration is not permitted 
until TB is treated to completion by directly observed therapy. Applicants with negative 
smears and cultures are permitted to emigrate within three months of negative cultures. After 





follow-up evaluation to detect and treat active TB or inactive TB (defined as LTBI with an 
abnormal radiograph).  
California TB Case Registry 
TB cases among Philippines-born persons reported from January 1, 2001 to 
December 31, 2010 were ascertained from the California Department of Public Health. 
Linkage of data sources 
Using established methods, (64) we linked pre-immigration records and California 
TB reports using Registry Plus™ LinkPlus 2.0, a probabilistic record linkage program (65). 
Records were matched on last name, first name, date of birth, year of exam, and gender. Two 
reviewers manually reviewed results, applying pre-determined rules to classify comparison 
pairs as true or false matches including: (1) exact match in all fields, (2) mismatch in a single 
field, (3) first/last name transposition, or (4) obvious typographical errors. In cases of 
disagreement, a third independent reviewer made the final classification. Improbable matches 
were those whose evaluation occurred after the date of TB diagnosis. 
Definitions and statistical analysis 
Immigrants were defined as individuals who received a permanent residency visa 
after screening in the Philippines. Likely LTBI reactivation was TB in an immigrant with a 
normal pre-immigration exam and radiograph (Figure 1). Imported TB was TB reported ≤6 
months after arrival in an immigrant with an abnormal pre-immigration radiograph. 
Reactivation of inactive TB was TB reported >6 months after arrival in an immigrant with an 
abnormal pre-immigration radiograph. 
Using lifetable methods, (66) we estimated annual TB rates following pre-





immigration radiograph evaluated with only sputum AFB smears (1991 guidelines), and, (3) 
abnormal pre-immigration radiograph evaluated with both sputum AFB smears and cultures 
(2007 guidelines). The date of pre-immigration exam was used for all rate calculations.  
To test whether hazard for LTBI reactivation changed with time in the US, we fit a 
cox regression model with year-specific effects with linear and quadratic terms to records 
from immigrants with normal pre-immigration radiographs. We compared the hazard for TB 
among immigrants with an abnormal radiograph evaluated according to 1991 and 2007 
guidelines using the survival and KMsurv packages in the R statistical suite, version 2.15.2. 
Results 
Cohort characteristics 
During 2001-2009, of 333,768 adult immigrants screened at SLMCEC, 123,114 
(37%) intended to settle in California. Of these, 17,160 (14%) had an abnormal pre-
immigration radiograph (Table 1). Immigrants with abnormal radiographs were significantly 
older, more frequently male, and more frequently had self-reported diabetes, history of 
tobacco use, and history of pulmonary TB than those with normal radiographs 
During 2001-2010, 4,324 Filipino adults were diagnosed with TB in California. For 
four individuals who had two episodes of TB, the second episode was excluded. Of the 3,900 
(90%) with a recorded US entry date, 1,316 (34%) reported entering during 2001-2009. Of 
these, 793 (60%) were linked to a pre-immigration record at SLMCEC (Figure 1). Four 
additional records matched to California TB reports before the date of pre-immigration 
evaluation and were excluded. Concordance between two independent reviewers during 





77% of California immigrants with abnormal pre-immigration radiographs. Of these, 82% 
were completed within 6 months of arrival.  
TB rate among immigrants with normal pre-immigration radiographs (likely LTBI 
reactivation) 
The rate of likely LTBI reactivation among immigrants with normal pre-immigration 
exam and radiograph was 31.6/100,000 person-years (py) during the first 9 years in the US. 
This rate did not change with increasing time in the US (p-value for trend in linear and 
quadratic models 0.8 and 0.5, respectively) (Figure 2a). In the initial year following pre-
immigration exam, likely LTBI reactivation represented a small fraction of TB diagnosed in 
the cohort. During year one, 33 (5.8%) of 568 TB cases were likely LTBI reactivation with 
the remainder classified as imported or likely reactivation of inactive TB. Conversely, during 
subsequent years, 171 (76%) of 225 TB cases occurring in the entire cohort were likely LTBI 
reactivation.  
TB rates among immigrants with abnormal pre-immigration radiographs 
TB rates among immigrants with abnormal radiographs differed depending on 
whether pre-immigration exam included AFB smears alone (1991 guidelines) or smears and 
mycobacterial culture (2007 guidelines). During the initial year following pre-immigration 
exam, TB rates among immigrants with abnormal radiographs evaluated according to 1991 
and 2007 guidelines were >100 and >25 times higher than among immigrants with normal 
radiographs (4,172 and 903/100,000 versus 31/100,000 py, respectively) (Figure 2b). Of 568 
immigrants with TB in the year following pre-immigration exam, 480 (84.5%), and 55 





abnormal pre-immigration radiographs and TB was reported within 6 months (imported), or 
after 6 months (reactivation of inactive disease) of arrival.  
Among immigrants with abnormal pre-immigration radiographs, TB declined 
markedly after the first year following pre-immigration exam. Rates among those evaluated 
according to the smear-based 1991 guidelines declined 40 to 50-fold compared with the next 
2-4 and 5-9 years (4,172/100,000 py versus 95/100,000 py and 82/100,000 py, respectively). 
Rates among those evaluated with both sputum smears and culture according to 2007 
guidelines declined from 903/100,000 py in the first year following pre-immigration exam to 
82/100,000 in years 2-4. Despite the decline during years 2-9, the TB rate among immigrants 
with abnormal radiographs was >3 times higher than among immigrants with normal 
radiographs (Hazard Ratio [HR] = 3.8, 95% Confidence Interval [CI] =2.6-4.8).  
Comparison with national surveillance data 
The TB rate in the entire California-bound cohort (normal and abnormal radiographs 
combined for comparison with existing surveillance data) was >10 times higher during year 1 
than during years 2-4 and 5-9 (463, 44 and 42/100,000 py, respectively). This rate is similar 
to recent US surveillance data which estimate TB rates among new entrants from the 
Philippines to be 500/100,000 during year 1 and 30-40/100,000 thereafter (53, 56). 
Impact of adding sputum culture to pre-immigration exam (2007 guidelines) 
After mycobacterial culture was added to the pre-immigration exam in October 2007, 
7.0% of applicants with abnormal radiographs had MTB positive sputum cultures and were 
therefore provided directly observed TB treatment prior to emigration. Of these, 74.8% were 
AFB smear negative and would not have been detected under previous screening guidelines. 





79% compared with persons evaluated according to the 1991 guidelines (Hazard Ratio [HR] 
= 0.21, 95% Confidence Interval [CI] = 0.16-0.28). Following implementation, an average of 
43 fewer imported TB cases were diagnosed each year compared with the pre-
implementation period (average 61/year pre-implementation versus 18/year post-
implementation). In years 2-9, TB risk among immigrants with abnormal radiographs did not 
differ based on whether or not they underwent sputum culture at pre-immigration exam (HR 
=0.63, 95% CI: 0.24-1.67).  
Age and TB rates 
Age-specific differences in TB rates between immigrants with normal and abnormal 
radiographs are illustrated in Figure 3. The age distribution of immigrants with abnormal 
radiographs is shifted “rightward” relative to those with normal radiographs reflecting 
substantially older age at entry. Among immigrants with normal radiographs, the TB rate was 
high in late adolescence, declined in the twenties then gradually increased to peak around age 
50 (Figure 3a). By contrast, among immigrants with abnormal radiographs, rates were 
>4,000/100,000 py in late adolescence and declined four-fold by 35 years of age with a slow 
decline with increasing age thereafter (Figure 3b). 
Clinical characteristics of likely LTBI reactivation and imported TB 
Likely LTBI reactivation and imported TB differed in ways likely to influence 
transmission risk (Table 2). Immigrants with imported TB were significantly more likely to 
be diagnosed with pulmonary TB than immigrants with likely LTBI reactivation (χ2 p-value 
<0.0001). Of those with pulmonary TB, immigrants with imported TB were significantly less 





inactive TB (23% smear positive, p=0.007) or likely LTBI reactivation (44% smear positive, 
p <0.0001). 
Discussion 
Among Filipino immigrants whose pre-immigration exam showed no evidence of 
active or inactive TB, the TB rate once in the US did not decline over a 9-year period, 
remaining approximately 25-times higher than the 2012 TB rate among US-born persons (2). 
Our findings are consistent with stable and persistent risk of LTBI reactivation. The 
perception that reactivation risk decreases over time has been based primarily on the 
observation that TB rates are highest immediately after arrival. In this cohort, high post-
arrival TB rates were entirely due to imported TB, likely detected through active post-arrival 
surveillance. Our observation of a sustained high risk of LTBI reactivation adds to mounting 
evidence that LTBI treatment should not be limited to the first 5 years after arrival in the US 
(59, 67).  
By distinguishing imported TB from likely reactivation TB, this cohort study 
provides critical insight into TB risk among immigrants and has important implications for 
clinicians and guidelines. The cause of the high TB rates consistently observed during initial 
post-arrival years in US national surveillance data (6, 7, 53, 56, 59) has been debated (55) but 
has generally been attributed to transiently increased risk of LTBI reactivation. Importantly, 
previous studies lacked pre-immigration exam data and were unable to estimate detection of 
imported TB through active post-arrival surveillance. The TB rate in our entire cohort 
(normal and abnormal radiographs combined) is consistent with previous surveillance 
estimates (53, 56) but stratification according to pre-immigration radiographic status 





immigrants with abnormal radiographs. Immigrants with normal pre-immigration 
radiographs (86% of immigrants in this cohort) had no excess TB risk in the immediate post-
arrival years.  
Our observation that TB risk among immigrants with normal pre-immigration 
radiographs does not decline over time is consistent with cohorts of refugees and asylum 
seekers to low-incidence settings including Denmark, (68, 69) Norway,(70) Canada,(71) 
Australia, and the US (72). These studies consistently report a high burden of prevalent 
imported TB that was detected through active post-arrival evaluation followed by persistently 
elevated TB incidence in ensuing years. Our estimates are consistent with studies from 
decades ago which observed TB rates of approximately 40-80/100,000 among immigrants 
with a normal pre-immigration radiograph during the first 4-5 years after their immigration to 
the US (60, 71, 72). A more recent US case control study did not identify evidence of 
decreasing reactivation risk with time (55).  
Pre-immigration evaluation is designed to detect and prevent importation of active 
TB among applicants with abnormal radiographs. Routine LTBI testing is conducted only for 
immigrants with abnormal radiographs who complete post-arrival follow-up. Our findings 
highlight that substantial further reduction in TB among immigrants will require expanding 
LTBI treatment among those with normal radiographs either overseas or after arrival (52, 59, 
67, 73). In this study, 86% of adult immigrants had a normal pre-immigration radiograph and 
this group accounted for 76% of TB diagnosed during years 2-9 (following the initial period 
of active detection of imported prevalent TB), likely due to progression of LTBI to active TB 
disease (4). Adding LTBI testing and treatment to the pre-immigration evaluation of adults 





by concerns about feasibility, cost effectiveness, and legal authority to delay immigration for 
persons who do not pose an immediate public health risk (74-77). The development of 
interferon gamma release assays and shorter-course weekly LTBI therapy (78) could 
potentially make overseas LTBI evaluation and treatment feasible.  
Expanding LTBI testing and treatment for foreign-born persons already in the US 
could also reduce the occurrence of domestic TB. Key challenges are, 1) current guidelines 
do not recommend LTBI evaluation for foreign-born persons in the US >5 years who do not 
have a coexisting medical or additional epidemiological risk, and, 2) existing LTBI 
recommendations are not effectively implemented (79, 80). Several lines of evidence suggest 
that restricting LTBI evaluation to the first 5 years leaves foreign-born persons at substantial 
TB risk. TB rates among Filipino immigrants in this cohort remained higher beyond 5 years 
post-arrival than in other groups currently recommended for LTBI evaluation (such as US-
born persons who are incarcerated or have medical conditions) (67). In 2011, 65% of TB 
cases among foreign-born persons were diagnosed >5 years after arrival (81). A recent cost-
effectiveness study identified the foreign-born in the US >5 years as the largest potential 
opportunity for domestic TB prevention (67). Finally, we note that the most desirable (and 
likely most cost-effective (76, 77)) means of preventing TB among the foreign-born in the 
US is reducing TB incidence in the countries of origin.  
By comparing two periods with distinct pre-immigration guidelines, our results 
support an earlier report (58) that enhanced screening has substantially reduced imported 
active TB. Before October 2007, applicants with abnormal radiographs received only AFB 
smears without mycobacterial culture. Due to the limited sensitivity of AFB smears, rates of 





Implementation of mycobacterial culture dramatically reduced (but did not entirely 
eliminate) imported active disease. Post-arrival follow-up evaluation therefore remains an 
important additional opportunity for case detection (10). Pre-departure treatment of 
applicants with evidence of culture-negative active TB or inactive pulmonary TB is a 
potential strategy to further reduce imported TB among screened immigrants. 
Our findings reinforce existing evidence that post-arrival follow-up prevents the 
spread of TB in the US (58, 82, 83). Immigrants with imported TB were less frequently 
sputum AFB smear positive than those diagnosed later, suggesting that active follow-up of 
immigrants with abnormal radiographs detects TB at an earlier, less infectious stage of 
disease. Evaluating and treating inactive TB (LTBI in immigrants with abnormal 
radiographs) is an important secondary priority of post-arrival evaluation. Effective LTBI 
evaluation and treatment or previous TB treatment may explain why the TB rate during years 
2-9 among persons with an abnormal pre-immigration radiograph was lower than in 
historical cohorts of patients with untreated inactive TB (84, 85).  
This study has several limitations. Our analysis is based on the conservative 
assumption that all applicants arrived and remained in California for capture of TB 
occurrence. Applicants who did not arrive would cause underestimation of the true rate in 
year 1. Persons who died or migrated out of California would cause underestimation during 
subsequent years. Second, our analysis considered only legal permanent residents from the 
Philippines but we believe results are likely to be similar for screened immigrants entering 
from other countries with high rates of TB. Immigrants account for only about 500,000 of 
over 30 million foreign-born US entrants each year. The remainder include students, business 





evaluation or active post-arrival follow-up and are therefore less likely to have early 
detection of imported TB. Third, we do not know whether immigrants with normal 
radiographs were evaluated and treated for LTBI after US arrival as guidelines recommend 
(9). We suspect most were not since a recent national survey indicated only 11.6% of 
foreign-born persons in the US with a positive tuberculin skin test reported prior treatment 
for TB or LTBI (86). LTBI treatment would contribute to a lower rate. Finally, we have 
assumed that the majority of TB among adult immigrants with normal pre-immigration 
radiographs resulted from TB exposures in the Philippines for two reasons. The likelihood of 
acquiring LTBI over a lifetime in the Philippines (TB incidence is >60 times higher than in 
the US) is substantially higher than acquiring LTBI in the US during a shorter period. 
Second, >96% of TB among Asians in California occurs among foreign-born persons, 
suggesting domestic transmission within Asian communities is relatively uncommon. It is 
conceivable that some primary TB occurs due to new exposures occurring during return 
visits to the Philippines but 80% of Filipinos with reported TB in California had not returned 
to the Philippines in the two years before diagnosis (unpublished data). Disease occurring 
due to TB exposures in the US or on return visits to the Philippines would cause 
overestimation of the LTBI reactivation rate but would not change our primary conclusions 
about the lack of decline in LTBI risk over time and the need to extend LTBI evaluation in 
this population.  
Conclusions 
In a large cohort of Filipino immigrants, the rate of likely LTBI reactivation TB 
among immigrants with a baseline normal pre-immigration screening exam did not decline 





imported active TB, likely detected as a result of active follow-up evaluation. Our findings 
suggest that current US guidelines should be revised to support LTBI screening and 
treatment among recently-arrived immigrants from high TB-burden countries beyond the 
current first 5 years. 
 
Table 1. Baseline characteristics of 123,114 California-bound Filipino adults during 2001-














 n (%)  n (%)   
Male 7,791 (45)  41,765 (39)  <0.0001
Age, years (median, IQR) 59 (47-67)  35 (22-52)  <0.0001
Medical risks at time of overseas 




 1,976 (12)  4,247 (4)  <0.0001
Current smoking 
a
 2,304 (13)  14,154 (13)  NS 
History of smoking 
a
 6,311 (37)  25,025 (24)  <0.0001
Renal insufficiency 
a
 89 (<1)  168 (<1)  <0.0001
Chronic hepatitis 
a
 28 (<1)  171 (<1)  NS 
Malignancy 
a
 302 (2)  581 (<1)  <0.0001
History of pulmonary TB 
a
 2,693 (16)  655 (<1)  <0.0001
Pre-immigration evaluation 
regimen b     
 
CDC 1991 guidelines 11,625 (68)  81,354 (77)   
CDC 2007 guidelines 5,535 (32)  24,600 (23)   
a
 Self-reported at time of pre-immigration exam. 
b 
After October 1, 2007, applicants with an abnormal radiograph underwent sputum culture in 








Figure 1. Study flow. Overseas, pre-immigration TB exam records for a cohort of 123,114 
California-bound Filipino applicants for permanent US residency were linked with the 











Figure 2. (a) Annual rates of likely LTBI reactivation among Filipino immigrants by year 
after overseas pre-immigration TB exam. (b) Annual TB rates by year overseas pre-
immigration exam among three strata of immigrants: (1) abnormal pre-immigration 
radiograph evaluated according to 1991 guidelines with sputum smears only (red), (2) 
abnormal pre-immigration radiograph evaluated according to 2007 guidelines with both 
sputum smears and cultures (blue) and (3) immigrants with normal pre-immigration 
radiograph (likely LTBI reactivation, black) Inset table summarizes estimated annual rates 
during Year 1, Years 2-4 and Years 5-9. Immigrants evaluated under 1991 and 2007 









Figure 3. Cumulative person-years (py) of observation (gray bars) and age-specific rate of 
TB diagnosis per 100,000 py (blue lines) (a) Among 105,987 Filipino immigrants with a 
normal pre-immigration radiograph young adults contributed most py of observation. The TB 
rate was high in late adolescence, dipped in the 20s and rose to peak around age 50 (b) 
Among 17,127 Filipino immigrants with abnormal pre-immigration radiograph elderly 
persons contributed the most py of observation. The TB was highest in the youngest age and 
declined consistently over time. Age-specific rates are smoothed with a centered weighted 








Table 2: Clinical characteristics of 793 adult Filipino immigrants evaluated at SLMCEC 




 TB diagnosed within 6-months of US arrival in an immigrant with an abnormal pre-
immigration radiograph. 
b
 TB diagnosis after 6-months of US arrival in an immigrant with an abnormal pre-
immigration radiograph. 
c
 TB diagnosed in an immigrant with a normal pre-immigration radiograph.  
d
 Significantly different from imported TB group (chi square p-value < 0.001) 
e 
Significantly different from imported TB group (chi square p-value < 0.01) 
f


















Primary site of disease         
Pulmonary 474
d
 99%  99
d
 91%  136 67% 
Pleural 1 <1%  3 3%  6 3% 
Lymphatic 1 <1%  3 3%  29 14% 
Other 1 <1%  3 3%  31 15% 
Missing 3 1%  1 1%  2 1% 
Sputum smear positive  60d 13%  23 e | 23%  60 44% 




71%  65 60%  103 50% 






BLOOD TRANSCRIPTIONAL BIOMARK ERS FOR ACTIVE TB AMONG US 
PATIENTS: A CASE-CONTROL STUD Y WITH SYSTEMATIC CROSS-
CLASSIFIER EVALUATION 2 
Introduction 
Early, accurate diagnosis of TB is critical for control of the global TB epidemic. 
However, the sensitivity of existing tests is inadequate (11). Most existing tests for active 
pulmonary TB are based on detection of MTB in sputum. However, the bacterium is not 
always present in detectable levels and sputum is not always obtainable. Since blood can be 
obtained from nearly all patients undergoing evaluation for pulmonary and/or 
extrapulmonary TB, a diagnostic test based on human markers in blood would be optimal 
(11).  
Human immune responses to MTB may lead to transcriptional patterns in blood that 
are not present in other conditions (87-89). Selected sets of mRNA transcripts have been 
used in prediction models to classify patient samples as having active TB or not (13-19). In 
early phase studies, (90) blood transcriptional classifiers have shown promise for active TB 
diagnosis (18, 19, 88, 91, 92) and monitoring treatment response (93).  
However, to move from proof of concept to an assay that is useful for TB control, it 
will be necessary to confront important practical questions. First, heterogeneity in diagnostic 
performance between populations is a well-known barrier to development of diagnostic tests 
                                                 
2 This chapter was previously published as: Walter ND, Miller MA, Vasquez J, Weiner M, Chapman A, Engle 
M, Higgins M, Quinones AM, Roselli V, Canono E, Yoon C, Cattamanchi A, Davis JL, Phang T, Stearman RS, 
Datta G, Garcia BJ, Daley CL, Strong M, Kechris K, Fingerlin TE, Reves R, Geraci MW. Blood transcriptional 
biomarkers for active tuberculosis among patients in the United States: A case-control study with systematic 






(94). Many genetic, environmental and technical factors affect transcriptional biomarkers 
(88, 95). Would a transcriptional classifier developed among sub-Saharan Africans (19) be 
similarly accurate among ethnically-diverse US patients? Existing blood transcriptional 
classifiers for active TB vary in the transcripts that are included, the populations from which 
they were derived, and in the prediction models used to derive them (13-19). To develop 
assays that can be implemented widely to improve TB control, it is critical to ascertain 
whether there is a “universal,” generalizable transcriptional pattern characteristic of TB (88).  
A second important practical question concerns the clinical usefulness of different 
types of blood transcriptional classifiers for TB. Three distinct classifier types have been 
based on different reference groups. The first type has compared active TB patients with 
systemically ill patients with other diseases that may mimic TB (15, 19). The second type has 
compared symptomatic TB patients with healthy subjects with LTBI (15, 19). The third type 
has compared active TB patients with combined groups of systemically ill patients and 
healthy persons (including individuals with LTBI) (13, 16, 19). To develop transcriptional 
classifiers as a patient care and public health tool, it is critical to evaluate the limitations and 
potential clinical applications of each of these three classifier types.  
We sought to develop a minimally invasive blood test to accurately diagnose active 
TB in racially and ethnically diverse populations. Therefore, we conducted a case-control 
study of blood microarray among US adults with and without TB and compared the 
transcriptional classifiers we identified with previously-published classifiers. We identified 
and tested three novel transcriptional classifiers that distinguish active TB from pneumonia 
(type 1), LTBI (type 2), and a combined group of LTBI or pneumonia (type 3). Additionally, 





cohort of sub-Saharan Africans and systematically evaluated the accuracy of previously-
published transcriptional classifiers when tested in our US patients. Finally, we assessed the 
limitations and potential clinical applications of the three classifier types. 
Methods 
Study design 
The expression in Pneumonia and Tuberculosis (ePAT) study was a prospective case-
control study of HIV-uninfected adults with and without pulmonary TB in Colorado (Denver 
Health Medical Center) and at TB control programs in Texas (details in Figure 1 and 
Appendix A). Three groups were enrolled. Adults with TB were sputum acid-fast bacillus 
smear and MTB culture positive. Adults with community-acquired pneumonia had cough or 
dyspnea, fever or leukocytosis, an infiltrate on chest radiograph, and a negative 
QuantiFERON®-TB Gold In-Tube (Cellestis) (QFT) result. Adults with LTBI had a positive 
QFT result and no cough, fever, weight loss or radiographic evidence of active TB. All 
patients were enrolled as outpatients; some were subsequently hospitalized. The Colorado 
Multiple Institutions Review Board and the University of Texas Health Sciences Center, San 
Antonio Institutional Review Board approved this project. All subjects provided written 
informed consent. 
Laboratory analysis, and data pre-processing 
Blood was drawn in PAXgene™ Blood RNA Tubes (QIAGEN). RNA was extracted 
using the PAXgene Blood RNA Kit (QIAGEN). Specimens with RNA Integrity Number >7 
via Bioanalyzer (Agilent) were considered acceptable. We selected 109 of 139 acceptable 
samples for microarray at random with stratification to achieve an approximate 1:1:1 ratio 





After quality inspection, expression data were Robust Multichip Average normalized, (96) 
log-transformed and adjusted for batch effect (97). Differential expression between groups 
was estimated using the R limma package, version 3.20.1 with a Benjamini-Hochberg 
correction for multiple comparisons. Transcripts with adjusted p-value <0.01 and absolute 
fold change of >1.2 were considered significant. 
Identification and evaluation of novel expression classifiers 
We identified three different classifiers that distinguish active TB from pneumonia 
(type 1), LTBI (type 2), and a combined group of pneumonia or LTBI (type 3). Samples were 
randomly partitioned into training (2/3) and test (1/3) sets. Transcript (feature) selection 
methods are detailed in Appendix A. Briefly, support vector machines with recursive feature 
elimination (SVM-RFE) (98) was applied to training set samples to identify transcripts most 
predictive of TB [e1071 package, version 1.6.3]. To determine the number of transcripts in 
each classifier, we identified the point at which adding additional transcripts did not 
substantially improve classification (details in Appendix A and Figure A1) (99, 100). 
Accuracy in the training set was estimated across 20 iterations of 6-fold cross-validation. 
After transcript selection, a new SVM was fit to training samples and used to predict the 
class of test set samples (details in Appendix A).  
For external validation, we used publically-available data from the largest published 
whole blood transcriptional classifier study (19) by Kaforou. Briefly, Affymetrix probeset 
IDs were converted to Illumina transcript IDs. Classification accuracy for an SVM using 






Evaluation of previously-published expression classifiers 
We systematically reviewed the published literature for transcriptional classifiers in 
adult human whole blood based on machine-learning classification of whole genome 
microarray data (details in Appendix A). To determine if transcriptional patterns observed in 
previously-published classifiers were also evident in our data, we compared median 
expression of transcripts from each published classifier with median expression of the same 
transcripts in our ePAT patients. To test previously-published classifiers in our cohort, we 
converted transcript identifiers to Affymetrix probeset IDs and estimated classification 
accuracy in cross-validation (6-fold, repeated 20 times) using the same classification method 
used in respective original manuscripts. Data are available in NCBI’s Gene Expression 
Omnibus [GSE 73408].  
Results 
Enrollment 
We screened 184 adults, enrolled 136 and conducted microarray for 109 samples 
identified via stratified random selection (Figure 1). Similar to the demographics of TB 
reported in the US (101), 63% of TB patients were foreign-born, from Southeast Asia, Africa 
and Latin America. TB patients more commonly reported diabetes (34%) than did patients 
with LTBI (9%, p = 0.02). TB patients were more commonly foreign-born (63%) than 
pneumonia patients (33%, p=0.01).  
Identification of novel ePAT transcriptional classifiers 
Using pneumonia as a disease reference group, our novel ePAT type 1 classifier included 47 





Confidence Intervals in Table 2). Specificity was 87.9% in the training set and 80% in the 
test set. Figure 2 shows Receiver Operating Characteristic (ROC) curves. 
For external validation, we applied our type 1 ePAT classifier to Sub-Saharan African 
subjects with and without HIV infection (19). Among HIV-uninfected Africans, sensitivity of 
the ePAT type 1 classifier was 90.2% and specificity was 77.7% (Table 2). Area Under the 
Curve (AUC) was significantly lower among HIV-uninfected Sub-Saharan Africans (90.6%) 
than among subjects in the ePAT training set (95.9%) (Figure 2) (p<0.001). Among Sub-
Saharan Africans with HIV infection, sensitivity was 84.8% and specificity was 76.3%. AUC 
was 88.6%, significantly lower than in the ePAT training set (p<0.001). 
Although the type 1 classifier was designed to distinguish TB from pneumonia, we 
additionally tested how it would classify LTBI samples. It distinguished TB from LTBI with 
100% (95% CI: 85.5-100%) sensitivity but only 40% (95% CI: 23.9-57.9%) specificity. AUC 
was 86.0% (95%CI: 76.5-95.5%). 
Our novel ePAT TB vs. LTBI classifier included 51 transcripts. Sensitivity was 
90.8% in the ePAT training set and 100% in the test set. Specificity was 90.4% in the training 
set and 81.8% in the test set. AUC was 95.9% in the training set and 98.4% in the test set. 
Figure 2 shows ROC curves.  
In external validation among Sub-Saharan African subjects without HIV infection, 
(19) sensitivity of the ePAT type 2 classifier was 90.4% and specificity was 86.4% (Table 2). 
AUC was 95.3%, not significantly different from the accuracy observed in US ePAT subjects 
(p=0.2) (Table 2). Among African subjects with HIV infection, AUC was 89.9%, 





To test the specificity of the type 2 classifier (designed to distinguish TB from LTBI) 
we applied it to pneumonia and LTBI patients. The ePAT type 2 classifier categorized 35 
(90%) of 39 pneumonia patients as TB, suggesting that it detects the presence of systemic 
illness rather than a signature unique to TB. When the ePAT type 2 classifier was applied to 
TB and pneumonia patients, 34 (87%) of 39 pneumonia patients were classified as TB. The 
transcripts differentially expressed in TB relative to LTBI are highly overlapping with the 
transcripts altered in pneumonia relative to LTBI (Figure 3). Of 1,611 transcripts with higher 
expression in TB than LTBI, 1,279 (74%) were also up-regulated in pneumonia relative to 
LTBI.  
Our final classifier included 119 transcripts that distinguished TB from a combined 
group of pneumonia or LTBI in ePAT samples. Sensitivity was 81.9% in the ePAT training 
set and 90.9% in the test set. Specificity was 79.0% in the training set and 76.9% in the test 
set (Table 2). The AUC was 85.6%, significantly lower than AUC for classifier types 1 
(p<0.001) or 2 (p<0.0001). 
In external validation, the type 3 ePAT classifier had higher accuracy among HIV-
uninfected Sub-Saharan Africans than among the US ePAT subjects used for classifier 
development (AUC 91.1% and 85.6%, respectively, p<0.001 ) Among Sub-Saharan Africans 
with HIV infection, AUC was 85.4%, not significantly different than the ePAT type 3 
classifier in ePAT patients. 
Evaluation of previously-published transcriptional classifiers 
Systematic literature review identified four published articles that developed 





These articles included two type 1 classifiers. Kaforou (19) compared active TB with 
a heterogeneous group of infections and neoplasms of the respiratory, genitourinay, and 
gastrointestinal tracts. When tested in US ePAT patients, the Kaforou classifier had an AUC 
of 82.9%, significantly lower than the ePAT TB vs. pneumonia classifier (p<0.001) (Table 
2). Berry (15) compared TB with various infectious and rheumatologic diseases. The Berry 
classifier had an AUC of 90.0%, also significantly lower than the ePAT TB vs. pneumonia 
classifier (p<0.001).  
There was little overlap (4.5%) in the transcripts included in different type 1 
classifiers (Table 3). To determine whether these different transcripts might nonetheless 
reflect the same biologic processes, we used DAVID Bioinformatics Resources (102) to 
quantify enrichment of Gene Ontology (GO) terms BP_Fat, CC_Fat and MF_Fat in the 
classifier transcript lists. This did not reveal shared GO terms (Appendix A). Finally, side-by-
side tornado plots provide visualization of global differences between studies in expression 
of transcripts included in classifiers. Figure 4a displays mean fold change for transcripts in 
the Kaforou type 1 classifier in Kaforou data. Figure 4b displays change in the same 
transcripts in ePAT data. The transcriptional change that distinguishes TB from OD in 
Africans is not clearly discernable among ePAT patients. Side-by-side tornado plots for the 
Berry classifier are included in Figure 5a-b. 
Our systematic review identified two type 2 classifiers (15, 19) that compared active 
TB to healthy controls with or without LTBI. When applied to ePAT data, the sensitivity and 
specificity of Berry (15) and Kaforou (19) type 2 classifiers were similar to that of the ePAT 





98.0%, significantly higher than the ePAT classifier in ePAT data (p<0.001). The AUC for 
the Berry type 1 classifier was 94.8%, significantly lower than the ePAT classifier (p<0.001). 
The average overlap in the list of transcripts included in type 2 classifiers was 33%, 
higher than for type 1 classifiers. Type 2 transcript lists were enriched for similar GO terms, 
including “innate immune response”, “response to wounding” and “defense response” 
(Appendix A).  In contrast to the type 1 classifiers, side-by-side tornado plots showed that the 
transcriptional changes that distinguished TB from LTBI among Sub-Saharan African 
subjects in the Kaforou study were clearly observable among ePAT patients (Figure 4c-d). 
Similarly, the transcriptional changes observed in the Berry dataset were also evident in 
ePAT subjects (Figure 5c-d).  
Finally, to determine whether misclassification of LTBI patients as TB is random or 
whether the same individual subjects are consistently misclassified by different classifiers, 
we evaluated the frequency with which each subject was misclassified in repeated cross-
validation. In Figure 6, the colored vertical bars indicate that two of 35 LTBI patients were 
consistently misclassified by all classifiers, suggesting that misclassification may result from 
an intrinsic difference in the patient sample rather than from random error. 
Systematic review identified three previous Type 3 classifiers (13, 16, 19) that 
compared TB to a combined group of healthy/LTBI and other diseases. When tested in US 
ePAT patients, the Kaforou type 3 classifier had an AUC of 82.8%, significantly lower than 
the ePAT type 3 classifier (p<0.001). Bloom (13) compared TB with a combined group of 
healthy persons and pneumonia, cancer and sarcoidosis patients. When tested in US ePAT 
patients, the Bloom classifier had significantly higher AUC than the ePAT type 3 classifier 





When tested in ePAT patients, the AUC was 90.4%, also significantly higher than the ePAT 
type 3 classifier (p<0.001).  
The average overlap in the list of transcripts included in type 3 classifiers was 4.1%. 
As was the case for type 1 classifiers, side-by-side tornado plots indicated that the 
transcriptional change observed in previous studies was not clearly discernable among ePAT 
patients (Figures 4e-f, 7a-b, 8a-b). 
Discussion 
We found that blood transcriptional classifiers accurately detected active TB among 
ethnically/racially diverse US adults. Our type 1 classifier was highly accurate in a common 
clinical challenge: distinguishing TB from pneumonia. However, the accuracy of classifiers 
for TB versus other diseases decreased when applied to new populations with different 
combinations of other diseases. Type 2 classifiers that distinguish TB from LTBI were highly 
accurate and generalizable across diverse populations. However, type 2 classifiers do not 
distinguish between TB and pneumonia. They are non-specific markers for systemic illness 
rather than signatures that are unique to TB. Transcriptional classifiers have potential to 
improve TB care and control but additional discovery and validation studies in diverse 
populations with different disease references are needed to identify the most predictive 
transcripts and generalizable signatures. 
Biomarker development is a multi-phase process, starting with pre-clinical 
exploratory studies, expanding to case-control and cohort studies and optimally culminating 
in randomized trials that demonstrate public health impact (90). It is essential to determine 
early in this process whether transcriptional classifiers are generalizable beyond the studies in 





transcriptional classifiers in a previously-unstudied population but also systematically 
evaluated the generalizability of our and previously-published classifiers. 
Type 1 classifiers address a high-priority clinical need by distinguishing active TB 
from other diseases that may mimic TB. We addressed a common clinical challenge: 
determining whether a patient with lower respiratory tract infection has TB. Our classifier 
was highly accurate among US patients. Accuracy diminished modestly (from AUC of 
96.5% to 90.6%) when applied to Sub-Saharan African patients with different disease 
reference groups. Previously-published classifiers were also less-than-optimally 
generalizable; accuracy was lower in ePAT patients than reported in original manuscripts. 
Type 1 classifiers developed independently in different studies (with different “other disease” 
reference groups) had very little overlap in transcript sets. Analysis of GO terms did not 
identify shared biological processes in different classifier transcript sets.  
The sub-optimal generalizability represents a key challenge for identifying a robust 
and universal transcriptional signature for TB versus other diseases (88). Unlike type 2 
classifiers that compare TB with a single reference condition (LTBI), a practically useful 
type 1 classifier would need to distinguish active TB from the protean range of infectious, 
neoplastic, and rheumatologic conditions that can mimic TB. A classifier optimized to 
distinguish TB from a single disease reference (such as lung cancer) may be less accurate in a 
different comparison (such as pneumonia). The essential next step for future studies will be 
identifying specific transcripts that are consistently predictive of TB versus the range of 
clinical mimics across different populations. This will require additional independent whole-
transcriptome classifier development in additional settings with additional disease 





Type 2 classifiers distinguish active TB from LTBI. Symptomatic active TB is 
associated with massive change in the blood transcriptome relative to healthy persons with 
LTBI, enabling accurate classification despite racial/ethnic diversity and medical co-
morbidities. Type 2 classifiers are remarkably accurate and generalizable across populations. 
When tested across different African, European and US settings, AUC was consistently 
~95% or higher. Studies conducted independently in different populations identified similar 
transcripts, representing similar immune and inflammatory processes. Tornado plots showed 
that the transcriptional patterns distinguishing TB from LTBI were remarkably consistent 
across studies.  
Unfortunately, type 2 classifiers do not represent a signature that is unique to TB. The 
transcriptional changes observed in TB relative to LTBI overlap nearly entirely with those 
observed in pneumonia relative to LTBI. It is therefore unsurprising that our type 2 classifier 
categorized nearly all pneumonia patients as having active TB. Type 2 classifiers essentially 
distinguish sick from healthy. Type 2 classifiers are therefore not useful in evaluation of 
systemically ill patients; for sick patients, the relevant question is not whether the patient is 
sick or healthy but whether the patient has TB or an alternative disease process (i.e., the task 
of type 1 classifiers). 
Could the type 2 classifier be used to identify individuals with incipient, sub-clinical 
active TB? We found that several LTBI patients were consistently misclassified as TB in all 
type 2 models. It has been proposed that LTBI patients who are misclassified as having TB 
could be at a transitional point between LTBI and active TB (15, 103). If a molecular 
signature of illness precedes the development of TB symptoms (104), type 2 classifiers might 





contacts of TB patients, health care workers in high TB incidence settings or HIV-infected 
persons. Since the type 2 classifier appears to be a non-specific marker of illness, positive 
screening results would lead to more intensive TB evaluation. This important potential 
application has yet to be tested.  
The third classifier type is an “all purpose” classifier designed to identify TB among 
patients that are either healthy or systemically ill. As a composite of the previous two 
classifier types, type 3 classifiers combine but do not resolve the challenges outlined above. 
As was observed in the Kaforou study, (19) our type 3 classifier was less accurate than our 
types 1 or 2.  
This study has several limitations. The limited sample size led to wide uncertainty 
intervals in the test set. Additionally, comparison between studies required conversion 
between microarray platforms, a methodological difference that tends to reduce 
generalizability (95). However, the use of different platforms makes the between-study 
consistency we observed in TB-LTBI classifiers an even stronger finding. Some transcript 
identifiers could be not converted because they have been retired from current annotation. 
Our conversion process therefore likely eliminated noise. A final obvious practical limitation 
is that there is currently no diagnostic platform that would make assays of blood 
transcriptional patterns feasible in high TB-incidence settings. Identification of an accurate, 
generalizable transcriptional classifier with a clear clinical application could motivate novel 
platform development.  
Conclusion 
Blood transcriptional classifiers are capable of accurately identifying active TB. A 





the breadth and heterogeneity of diseases that may mimic TB. Additional studies of 
systemically ill patients in diverse settings with systematic assessment of cross-study 
generalizability are needed. Classifiers comparing TB and LTBI do not identify a signature 
that is unique to TB but should nonetheless be explored as a screening tool in high risk 
asymptomatic or minimally symptomatic persons. Blood transcriptional assays that enable 






















TB LTBI  Pneumonia 
n = 35 n = 35 p-valuea  n = 39 p-valuea 
Male  25 (71) 18 (51) 0.08  23 (59) 0.3 
Foreign-born  22 (63) 30 (86) 0.06  13 (33) 0.01 
Race/ethnicity    
Asian  6 (17) 14 (40) 0.06  2 (5) 0.1 
Black  2 (6) 6 (17) 0.3  5 (13) 0.3 
Latino  23 (66) 9 (26) <0.001  16 (41) 0.03 
White  3 (9) 1 (3) 0.6  11 (28) 0.04 
Other  1 (3) 5 (14) 0.2  5 (13) 0.02 
Age     
18-34  10 (29) 15 (43)   3 (8)  
35-49  7 (20) 13 (37)   16 (41)  
50-64  10 (29) 5 (14)   10 (26)  
>65  8 (23) 2 (6)   10 (26)  
Diabetes  12 (34) 3 (9) 0.02  9 (23) 0.3 
Asthma or COPD  6 (17) 4 (11) 0.04  11 (28) 0.2 
Current smoker  10 (29) 8 (23) 0.6  16 (41) 0.3 
a





Table 2. Accuracy of three types of whole-blood transcriptional classifiers for active TB. For 
each classifier type, results are shown for ePAT training and test sets and external validation 
in Sub-Saharan African patients with and without HIV infection. Additionally, results are 
shown for previously-published classifiers when tested in ePAT patients.  







Type 1: TB versus Pneumonia classifier 
ePAT type 1 classifier in ePAT patients 
Training Set 
TB = 24  








TB = 11  







External validation in African patients  
HIV-negative 
TB = 97  







HIV-positive TB = 102  







Previously-published type 1 classifiers in ePAT patients 
Kaforou 
TB = 35  







Berry TB = 35  







Type 2: TB versus LTBI classifier 
ePAT type 2 classifier in ePAT patients 
Training Set 
TB = 24  








TB = 11  







External validation in African patients  
HIV-negative 
TB = 97  















Previously-published type 2 classifiers in ePAT patients 
Kafrorou 
TB = 35  








TB = 35  











Table 2 continued 
  







Type 3: TB versus LTBI or pneumonia classifier 
ePAT type 3 classifier in ePAT patients 
Training Set 
TB = 24  
















External validation in African patients  
HIV-negative  
TB = 117  








TB = 121  







Previously-published type 3 classifiers in ePAT patients 
Kaforou 
TB=35  





























Table 3. Overlap in the transcripts included in seven previously-published classifiers and the 
three novel transcriptional classifiers developed in this study. Gray cells represent the 
number of unique transcripts in each classifier after conversion to Affymetrix probeids. 
Yellow shading indicates between-study overlap in classifiers for TB vs. LTBI. Pink shading 
indicates between-study overlap in classifiers for TB vs. other diseases (OD) or pneumonia 












Figure 2. ROC curves for three different transcriptional classifier types. TB versus 
pneumonia classifier in (A.) ePAT training set, (B.) ePAT test set, (C.) External validation in 
HIV-uninfected Sub-Saharan Africans, (D.) HIV-infected Sub-Saharan Africans. TB versus 
LTBI classifier in (E.) ePAT training set, (F.) ePAT test set, (G.) External validation in HIV-
uninfected Sub-Saharan Africans, (H.) HIV-infected Sub-Saharan Africans. TB versus 
pneumonia or LTBI in (I.) ePAT training set, (J.) ePAT test set, (K.) External validation in 







Figure 3. Venn diagram of transcripts differentially expressed in TB relative to LTBI and 
pneumonia relative to LTBI. (A.) Transcripts with significantly lower expression in TB and 
pneumonia than in LTBI (Benjamini-Hochberg adjusted p-value <0.01 & fold change >1.2). 









































Figure 4. Comparison of transcriptional changes in Kaforou classifiers in the Kaforou study 
and ePAT. (A.) Mean fold-change (log2 scale) of 44 transcripts in the Kaforou TB versus 
other diseases classifier in the original Kaforou study. Rows represent individual transcript 
identifiers. Blue bars indicate transcripts with increased expression in TB in the original 
manuscript; red represents decreased expression in TB in the original manuscript. (B) Mean 
fold-change for the same 44 transcripts among ePAT patients with TB and pneumonia. (C) 
Mean fold-change for 27 transcripts in the Kaforou TB versus LTBI classifier in the original 
Kaforou study. (D) Mean fold-change for the same 27 transcripts among ePAT patients. (E) 
Mean fold-change for 53 transcripts in the Kaforou TB versus LTBI or other diseases 
classifier in the original Kaforou study (F) Mean fold change for the same 53 transcripts 



























Figure 5. Comparison of transcriptional changes in Berry classifiers in the Berry study and 
ePAT. (A.) Mean fold-change (log2 scale) of 86 transcripts in the Berry TB versus other 
diseases classifier in the original Berry study. Rows represent individual transcript 
identifiers. Blue bars indicate transcripts with increased expression in TB in the original 
manuscript; red represents decreased expression in TB in the original manuscript. (B) Mean 
fold-change for the same 86 transcripts among ePAT patients with TB and pneumonia.  (C) 
Mean fold-change for 393 transcripts in the Berry TB versus LTBI classifier in the original 








Figure 6. Consistency of misclassification of TB and LTBI patients by previously-published 
TB/LTBI classifiers and our ePAT classifiers. Columns represent individual subjects. 
Colored headers indicate subjects’ true class: blue = TB, gray = LTBI. Green cells represent 
instances in which the classifier assigned the correct class with a high degree of certainty 
(probability of the correct class estimated as >0.66). Yellow cells represent instances in 
which the classifier did not have high certainty (probability of correct class estimated as 
between 0.33 and 0.66). Red cells represent instances in which the classifier assigned the 
incorrect class (misclassification) with a high degree of certainty (probability of correct class 
estimated as <0.33). The presence of columns of red and yellow suggest that different 











































Figure 7. Comparison of transcriptional changes in Berry classifiers in the Bloom study (7) 
and ePAT. (A.) Mean fold-change (log2 scale) of 140 transcripts in the Bloom TB versus 
other diseases or LTBI classifier in the original Bloom study. Rows represent individual 
transcript identifiers. Blue bars indicate transcripts with increased expression in TB; red 
represents decreased expression in TB. (B) Mean fold-change for the same 140 transcripts 














































Figure 8. Comparison of transcriptional changes in Maertzdorf classifiers in the Maerzdorf 
study and ePAT. (A.) Mean fold-change (log2 scale) of 100 transcripts in the Maertzdorf TB 
versus other diseases or LTBI classifier in the original Maertzdorf study. Rows represent 
individual transcript identifiers. Blue bars indicate transcripts with increased expression in 
TB; red represents decreased expression in TB. (B) Mean fold-change for the same 100 







TRANSCRIPTIONAL ADAPTATION OF DRUG-TOLERANT MYCOBACTERIUM 
TUBERCULOSIS DURING HUMAN TUBERCULOSIS 3 
Introduction 
Drug-tolerant bacterial phenotypes play a central role in human TB, a disease that 
kills 1.5 million people each year (1). In patients treated for drug-susceptible TB, >99% of 
the MTB population is killed within the first 3-5 days (25, 27, 105). Thereafter, the rate of 
killing decreases by >80% (25, 27, 105) indicating that surviving bacterial population is drug 
tolerant. Drug tolerance differs from drug resistance. Resistance results from mutations in 
specific genetic loci. Tolerance is a reversible phenotypic state that occurs in the absence of 
resistance-conferring mutations (23).    
Drug tolerance is a central challenge for drug development and global TB control. 
Most forms of TB require at least six months of treatment to eradicate slowly-killed, drug-
tolerant MTB populations and minimize risk of treatment failure and relapse (106, 107).  
This duration burdens patients and health systems and contributes to medication non-
adherence, enabling further transmission and acquired drug resistance (22). 
Little is known about drug-tolerant MTB in human TB. Genetically homogeneous 
bacterial populations are hypothesized to include heterogeneous bacterial phenotypes (108, 
109). Phenotypes capable of surviving prolonged antibiotic exposure despite genetic 
susceptibility have been called persisters (23). However, it is unknown whether there is a 
single MTB persister phenotype or a spectrum of drug-tolerant phenotypes. Drug tolerance is 
                                                 
3 This chapter was published as: Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, 
Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris KJ, Palmer C, Nahid P, 
Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL. Transcriptional adaptation 
of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis. J Infect Dis 2015; 





observed under a variety of experimental conditions (31, 32, 35, 46-48, 110) but it is 
unknown whether these models recapitulate drug-tolerant phenotypes in human TB (23). 
There is currently no marker or method for identifying distinct phenotypes within an isogenic 
MTB population. A better understanding of the clinically-relevant drug-tolerant population 
detectable in TB patients during treatment is essential to developing novel, shorter treatment 
regimens that will improve globalTB control and individual patient outcomes. 
We used multiplex qRT-PCR gene expression profiling to characterize the metabolic 
state and adaptive mechanisms of drug-tolerant MTB remaining in sputum after the early 
bactericidal phase of treatment. mRNA expression provides a contemporaneous measure of 
bacterial physiologic state since the estimated half-life of MTB mRNA is 9.5 to 50 minutes 
(111) and mRNA is not detectable from dead bacilli (33). To identify the transition from 
rapid to slow killing that is the hallmark of a drug-tolerant bacterial population, we evaluated 
change in the abundance of MTB genomic DNA, 16S ribosomal RNA and mRNA over time. 
We analyzed gene expression profiles, identifying change in functional gene categories that 
reflect the physiologic state of the drug-tolerant population. We examined the expression of 
genes previously associated with drug tolerance, including efflux pumps, drug-activating 
enzymes, drug targets, and the isoniazid stress signature. Finally, we compared MTB 
expression patterns in TB patients undergoing treatment with expression patterns in 
experimental models of drug tolerance (35, 46-48, 110).  
Methods 
Enrollment and specimen collection 
A random sample of consecutive adults with pulmonary TB were enrolled at Mulago 





treatment (day 0) and after 2, 4, 7, 14, 28 and 56 days, patients expectorated into a sterile cup 
containing guanidine thiocyanate solution for immediate RNA preservation (39). Within two 
hours, sputa were needle-sheared, centrifuged at 9000xg, and stored in Trizol at -80°C. 
Ugandan and US institutional review boards approved the study. All patients provided 
written informed consent.   
Expression profiling  
Total RNA was extracted using a phenol/chloroform protocol described in the 
Supplement. After first strand cDNA synthesis, cDNA underwent controlled multiplex 
amplification using MTB-specific flanking primers as previously described (112). Expression 
of 2,411 MTB transcripts was quantified via multiplex qRT-PCR with a LightCycler 480 
(Roche, Indianapolis, IN) using TaqMan primers. 
Analysis 
We plotted mRNA, 16S rRNA, and DNA abundance over time relative to baseline 
values. We fitted the change in geometric mean percentage over time with 95% confidence 
intervals using saturated linear mixed models. mRNA expression data were normalized using 
a minimum variance data-driven method (113). We identified altered gene expression at days 
2, 4, 7, and 14 relative to day 0 via paired-t tests with Benjamini-Hochberg (114) multiple 
testing correction using a false discovery rate of 0.05. To identify highly expressed genes, 
expression values for each sample were ranked from one (gene with lowest expression) to 
100 (highest expression). The median percentile rank of each gene at each day was 
calculated. 
To identify bacterial functions that changed with drug treatment, we summarized the 





or decreased expression from day 0 with an unadjusted p-value <0.05. A modified one-way 
Fisher’s exact test (115) was used to identify enriched functional categories (p-value 
threshold <0.05). 
Data from days 28 and 56 were not normalized because of low transcript detection. 
To evaluate similarity in expression across days 14-56, we quantified between-day overlap in 
the genes consistently detected in >50% of samples.   
Non-specific changes were defined as genes that were significantly induced or 
suppressed both immediately after drug exposure (day 2) and at all subsequent time points. 
Genes significantly altered between days 2 and 14 were considered likely specific to drug-
tolerant bacilli. Hierarchical clustering using a Euclidean distance was performed on the 
median fold change from day 0 for tolerance-associated genes. A static tree cut at height 4 
was used to create 5 distinct clusters.  
Enrichment of functional gene categories was compared between sputum and five 
experimental models. For sputum and each model, the ratio of genes up- and down-regulated 
was calculated for each functional category and log2 transformed.  Pearson’s correlation 
coefficients were calculated between each model pair using the log2 transformed values. 
Analysis used the R statistical suite, version 3.0.1 except as noted in Supplement. MIAME-
compliant data are available at http://www.tbdb.org/rtpcrData.shtml. 
Results 
Seventeen Ugandan adults with drug-susceptible, sputum acid-fast bacillus smear-
positive, culture-positive pulmonary TB were enrolled (Figure B1, Table B1). Nine were 





After two months, four remained sputum MTB-culture positive. One patient had recurrent 
TB 13 months after completing treatment.  
Change in nucleic acid abundance 
 MTB mRNA abundance declined 0.55 log/day during days 0-4, consistent with rapid 
killing during the early bactericidal phase (Figure 1). After day 7, the decline in mRNA 
abundance slowed to 0.03 log/day (slowing 94% relative to day 0-4), consistent transition to 
a drug-tolerant population. 16S rRNA and DNA declined more slowly. 16S rRNA transcripts 
per genome equivalent of DNA declined 96-99% from day 0 to days 14 through 56, 
consistent with a slowing of replication. All samples, including those that were culture 
negative after 56 treatment days, had greater than100 MTB mRNA transcripts detected, 
indicating the presence of a viable, but not culturable population, as previously reported 
(116-119). 
MTB transcriptional alteration during treatment 
Treatment markedly altered the bacterial transcriptome. Relative to pre-treatment 
expression, the abundance of 452 (19%) transcripts increased and 741 (31%) transcripts 
decreased significantly during treatment days 2, 4, 7, and 14 after adjustment for multiple 
comparisons.  
Key functional categories with altered gene expression during drug treatment are 
shown in Figure 2 (Categories are defined in Table B2). Expression of genes associated with 
metabolic processes was predominantly down-regulated. Expression of genes involved in 
aerobic respiration, the tricarboxylic acid (TCA) cycle, and ATP synthesis decreased 
immediately and remained suppressed through day 14. By contrast, expression of genes 





increased significantly by day 14. Genes of the glyoxylate bypass, an alternative to the TCA 
cycle were down-regulated yet remained among the most highly-expressed genes.  
Expression of genes coding for ribosomal proteins and other genes such as translation 
elongation factor (tuf, Rv0685) was rapidly down-regulated, suggesting a global decrease in 
protein translation. Down-regulation of polyketide synthase gene expression suggested 
diminished production of cell envelope lipids. Genes coding for the ESX/Type VII system 
which secretes highly immunogenic virulence factors including ESAT-6 were highly 
expressed prior to treatment but were down-regulated with treatment, particularly at days 7-
14. Expression of genes central to DNA replication including DNA gyrase subunit A (gyrA), 
subunit B (gyrB) and DNA topoisomerase I (topA) was significantly down-regulated during 
days 7-14. 
Genes typically induced by stress had increased expression including: oxidative stress 
response, the immunogenic PE/PPE genes and insertion sequences and phages. There was 
induction of genes for the enduring hypoxic response, a response induced in vitro by 
prolonged hypoxia and other stressors. In contrast, expression of DosR regulon genes that are 
induced in vitro by hypoxia and other conditions that inhibit aerobic respiration was 
significantly down-regulated in sputum on day 14. Expression of the gene for RelA, the 
regulator of the starvation-associated stringent response, increased significantly on day 2 but 
not on subsequent days. The stringent response expression signature includes induction of 
specific stress-associated gene sets and suppression of ribosomal protein mRNA and other 
genes (120). Genes classically induced during the stringent response did not have 





described as suppressed during the stringent response did have significantly decreased 
expression on days 2, 4, 7 and 14. 
Three categories of regulators – sigma factors, transcription factors and toxin-
antitoxin (TA) modules – were markedly altered. Expression of the gene for SigA, the 
principal growth-associated sigma factor, was suppressed. Conversely, expression of genes 
for stress-associated sigma factors including SigB, SigE, SigF, SigH, SigI and SigJ increased 
significantly. Expression of genes coding for toxins were upregulated – particularly of the 
VapBC family which cleave existing mRNA to rapidly remodel the transcriptome in 
response to stress. 
Transcriptome analysis after day 14 was limited because mRNA abundance was 
insufficient. However, transcripts consistently detected (present in >50% of samples) at days 
14, 28 and 56 overlapped almost entirely, suggesting a stable expression pattern during the 
sterilizing phase of treatment.  
Drug-induced stress responses versus adaptations specific to the drug-tolerant 
population 
Gene expression in MTB has previously been stratified into: non-specific drug-
induced stress responses and transcriptional adaptations that are specific to the drug-tolerant 
population (35). We defined non-specific responses as genes significantly induced or 
suppressed immediately after drug exposure (day 2) with changes sustained at all subsequent 
time points. Of 104 non-specific stress response genes, 64 were consistently induced and 40 
were consistently suppressed. Induced genes were statistically enriched for the enduring 
hypoxic response (p=0.003). Suppressed genes were enriched for metabolism genes involved 





To identify transcriptional adaptations specific to drug-tolerant bacilli, we identified 
82 genes whose expression changed significantly between day 2 and day 14 of drug 
treatment (Figure 3A). Clustering by treatment day showed progressive expression change 
with increasing duration of treatment. Days 7 and 14 clustered closely together, suggesting 
transition to a stable drug-tolerant phenotype. Clustering of genes over time identified 
subsets with similar patterns of expression change, suggesting a coordinated role in 
development or maintenance of drug-tolerant bacilli (Figure 3B). Clusters A and B (35 
genes) demonstrated little to no change between days 0 and 2, but significant induction by 
days 7 and 14. These included triacylglycerol synthases, and ABC transporter and toxin 
molecules. Clusters C and D (9 genes) were strongly induced immediately following 
antibiotic exposure (day 2) and were notable for three genes in the KAS operon required for 
mycolic acid synthesis. Cluster E (38 genes) was significantly down-regulated at days 7 and 
14; it consisted primarily of ESX and ribosomal genes. 
Expression of antibiotic-associated genes 
We evaluated genes for proteins previously associated with drug tolerance or 
resistance, including efflux pumps, drug-activating enzymes, drug targets and the isoniazid 
stress signature. As a category, efflux pump genes were not significantly enriched following 
treatment initiation. However, a subset of efflux genes shown in vitro to export drugs – 
including the Tap protein coded for by Rv1258c, bacA (Rv1819c), and mmr (Rv3065) –were 
induced >3-fold during days 7-14. 
Decreased expression of genes coding for drug-activating enzymes – katG 





drug tolerance. However, after seven to 14 treatment days, the expression of these genes was 
not suppressed. 
Drug tolerance could also result from increased expression of drug targets. 
Expression of the gene for rifampicin target DNA-dependent RNA polymerase (RpoB) was 
significantly induced at all intervals after treatment initiation. Expression of the gene for 
isoniazid target InhA did not change significantly. In contrast, genes for DNA gyrase 
subunits (GyrA, GyrB) which are targeted by fluoroquinolones (drugs these patients did not 
receive) had progressively decreased expression, consistent with decreased replication. 
Similarly, expression of the gene for bedaquiline target AtpE was suppressed at all intervals, 
consistent with down-regulation of aerobic metabolism.  
We examined the effects of drug treatment on the isoniazid stress response – a set of 
mycolic acid synthesis and stress response genes previously shown to be induced and 
inversely proportional to growth rate during in vitro isoniazid exposure (30, 121-123). After 
two treatment days, the isoniazid stress signature was robustly induced in sputum, including 
mycolic acid biosynthesis genes (fabD, acpM, kasA, kasB, accD6), an efflux gene (efpA), and 
an oxidative stress response gene (aphC). After seven days, this signature was no longer up-
regulated, consistent with the known poor sterilizing activity of isoniazid (124). 
Comparison with experimental models of  MTB drug-tolerance  
To test whether existing experimental models recapitulate drug-tolerant MTB in 
humans, we compared gene expression in sputum with five widely-cited experimental 
models  (35, 46-48, 110). As in sputum, all models identified down-regulation of ribosomal 
proteins and TCA cycle, aerobic respiration and ATP synthesis genes, indicating slowing of 





up-regulation of the enduring hypoxic response, and most found up-regulation of oxidative 
stress responses. Notably, the oxygen-responsive DosR regulon was induced in models that 
applied hypoxic stress (41, 46-48) but not in sputum, the antibiotic selection model (35) or 
the nutrient starvation model (110). The stringent response regulator relA was induced in the 
nutrient starvation model, (110) the hollow-fiber granuloma model, (30) and the oxygen 
deprivation model (48). The initial transient induction of relA at day 2 in sputum is similar to 
the antibiotic selection model (35) in which relA was significantly induced after one day of 
drug exposure but then significantly down-regulated after 7 and 14 days. Drug-tolerant MTB 
in sputum had greater up-regulation of genes involved in regulatory functions – TA modules, 
sigma factors, and transcription factors – than did several models (41, 47, 110). Sputum MTB 
also had greater induction of PE/PPE genes and insertion sequences and phage genes than 
most models (35, 47, 48). Overall, expression in sputum was most similar to the antibiotic 
selection model (35) (Pearson correlation coefficient 0.73).  
Discussion 
This study provides the first direct characterization of drug-tolerant MTB during 
human TB treatment, a refractory population that dictates the components and duration of TB 
treatment. Gene expression of drug-tolerant bacilli suggests slowing of growth and metabolic 
and synthetic down-regulation. Nonetheless, the drug-tolerant population is not 
transcriptionally dormant. Rather, up-regulation of genes involved in stress responses, drug 
efflux, and regulatory functions indicate active transcriptional reprogramming. 
Understanding the adaptations of drug-tolerant bacilli in vivo should aid development of 





Several lines of evidence indicate that MTB present in sputum after 14 days of 
treatment is drug-tolerant. Previous in vitro (35) and human data (125) indicate that seven 
days of drug exposure clears rapidly-killed bacilli, leaving a drug-tolerant population. 
Through serial sputum sampling, we identified a biphasic decline of MTB mRNA 
characteristic of early bactericidal activity studies (25, 27, 105). The slowdown in killing 
after the bactericidal phase is the clinical hallmark of drug-tolerance (25, 27, 105).  
Whether drug-tolerant MTB phenotypes continue replication or become non-
replicating is intensely debated (23, 34, 126). Our gene expression data do not provide a 
direct measure of growth rate but the following observations suggest decreased replication: 
16S rRNA per genome equivalent of DNA declined 96-99% from day 0 to days 14-56; genes 
coding for ribosomal proteins were strongly down-regulated; and expression of DNA gyrases 
and topoisomerases was suppressed. Conversely, the continued detection of transcripts for 
ribosomal proteins and DNA synthesis functions suggests that replication may not cease 
entirely.  
Drug-tolerant MTB are metabolically down-regulated but are not transcriptionally 
dormant. Induction of multiple stress responses and of genes with regulatory functions 
indicates active transcriptional reprogramming in response to environmental conditions. Our 
data support the role of growth-inhibiting TA modules in mediating transition to and 
maintenance of drug tolerance through post-transcriptional regulation (127, 128).  
We evaluated mechanisms hypothesized to contribute to drug tolerance. Slow growth 
decreases drug effectiveness, (30, 46-48) likely because antibiotics generally target 
replication-associated functions. Drug-tolerant MTB had increased expression of genes for 
efflux pumps which export rifampicin and isoniazid (129, 130).
 





that pharmacologic efflux pump inhibition might shorten treatment regimens (131). 
Conversely, drug tolerance is not readily explained by regulation of drug-activating enzymes. 
In vitro data suggest that one tolerance mechanism is suppression of katG expression leading 
to diminished isoniazid activation (34, 132). We did not identify down-regulation of katG in 
vivo. However, this does not rule out the possibility that decreased katG expression occurs in 
a subset of drug-tolerant bacilli or fosters the initial formation of drug-tolerance after 
isoniazid exposure. Drug tolerance was not readily explained by altered expression of drug 
targets. Induction of rpoB in drug-tolerant MTB could be compensatory adaptation for 
rifampicin’s inactivation of RNA polymerase. Alternatively, it could indicate a general 
stress-induced increase in transcriptional reprogramming. In either case, rpoB over-
expression has not been associated with resistance (133). Increased expression of the gene for 
isoniazid target InhA causes low-level resistance, (124) but, as in experimental models, (35, 
36, 110, 121) inhA was not induced in drug-tolerant MTB in sputum. Drug-tolerant MTB had 
decreased expression of genes for fluoroquinolone targets GyrA and GyrB and bedaquiline 
target AtpE. Since patients were not administered these drugs, this may reflect down-
regulation of replication and aerobic metabolism as part of a broader regulatory program 
rather than drug-specific responses. 
These results have clinical implications. We have shown that monitoring bacterial 
physiology during human TB treatment is feasible through MTB expression profiling. 
Practical applications– including monitoring response to novel drugs or as biomarkers 
predictive of treatment failure or relapse – should be evaluated (134). Detection of 
transcriptionally active bacilli after two months of treatment – including in culture negative 





bacilli (135). Importantly, our findings indicate that standard doses of rifampicin – an 
inhibitor of transcription initiation – fail to fully interrupt bacterial gene expression. Evidence 
suggests higher rifampicin doses may improve killing and shorten treatment durations (136). 
Prior to this study it was not possible to test whether experimental models that inform 
current understanding of drug tolerance and are used for early-stage drug development 
successfully recapitulate MTB phenotypes in human TB. Gene expression of drug-tolerant  
MTB in sputum was most similar to an in vitro model that uses antibiotic exposure alone in 
the absence of hypoxia or other adverse conditions to select for drug-tolerant MTB (35). 
Drug-tolerant MTB in sputum did not have increased expression of the DosR regulon that is 
characteristic of models that use hypoxia (41, 47, 48) or hypoxic tissue conditions (46). 
Genes of the DosR regulon were highly expressed in sputum prior to drug exposure in our 
data and in a previous study, (39) but were not further induced by treatment. This indicates 
that drug tolerant bacilli are not necessarily in a more hypoxic environment than drug 
susceptible bacilli. The transient induction of relA we observed in sputum is consistent with 
the antibiotic selection model but not with nutrient-limited models. RelA with consequent 
ppGpp synthesis, may direct the initial formation of drug-tolerant phenotypes. Alternatively, 
it is possible that the stringent response is not robustly expressed in drug-tolerant MTB in 
sputum because antibiotic exposure may not alter nutrient availability.  
Treatment failure and relapse are surmised to result from drug-tolerant MTB persister 
bacilli. However, there is no direct evidence or scientific consensus regarding the nature of 
the MTB persister phenotype (23) or even whether a single persister phenotype exists (22, 
109). The drug-tolerant MTB population we studied in sputum meets a proposed functional 





susceptibility (23). Nonetheless, since it is not currently possible to distinguish between 
bacterial phenotypes or track individual bacilli in humans, we cannot prove that the drug-
tolerant  MTB present in sputum represent the hypothesized persister phenotype.  
This study has several limitations. The sample size did not permit correlation of 
bacterial expression with clinical outcomes. Although phenotypic drug-susceptibility testing 
was not performed, MTB strains profiled in this study were likely drug-susceptible since 
rates of primary drug resistance in Uganda are low (137) and no rifampicin resistance-
conferring mutations were detected with GeneXpert MTB/RIF.  
Conclusion 
We provide the first genome-wide description of the transcriptional adaptations of 
drug-tolerant MTB during human TB treatment. Our data suggest a shift in the mycobacterial 
population to a slowly replicating, metabolically down-regulated phenotype that no longer 
displays signals of isoniazid-induced stress. Our findings reinforce the critical need for novel 
anti-TB drugs to target the recalcitrant drug-tolerant bacterial population, leading to more 









Figure 1. Decline in  MTB mRNA abundance among 17 patients during the first 56 days of 
TB treatment. The solid line represents the geometric mean percentage of mRNA abundance 










Figure 2. Change in expression of selected functional categories of genes after initiation of 
TB treatment. The percentage of genes in each category significantly up- (yellow) or down 
(blue) regulated at each day relative to pre-treatment expression (Day 0) is illustrated.  
Categories are ordered from most up-regulated (top) to most down-regulated (bottom). 
Category references are provided in the Online Supplement, Table S4. 
 
Abbreviations: EHR, enduring hypoxic response; IS & phages, insertion sequences and 






Figure 3. (A) Heatmap of median expression fold-change of 82 genes differentially 
expressed (adjusted p-value <0.05) between the early bactericidal phase (Day 2) and 
sterilizing phase (Day 14). Yellow indicates increased expression relative to day 0; blue 
indicates decreased expression. Clustering by day (row) indicates similarity between 
expression patterns at different days. Clustering by gene (column) identifies five clusters of 
genes (A-E) with similar expression patterns over time. (B) Fold change in expression of 









Figure 4. Comparison of enrichment of functional gene categories between drug-tolerant  
MTB in sputum and selected experimental models. (A) Sputum after 14 days of drug 
treatment, (B) Antibiotic selection model (Betts 2011), (C) Hollow fiber artificial granuloma 
model (Karakousis 2004), (D) Nutrient starvation model (Betts 2004). (E) Oxygen 
deprivation non-replicating persistence model (Voskuil 2004), (F) Multiple-stress model 
(Deb 2004).  
  
  







MYCOBACTERIUM TUBERCULOSIS ADAPTATION TO IMPAIRED HOST 
IMMUNITY IN HIV-INFECTED PATIENTS 
Introduction  
TB is the leading cause of death in HIV, killing an estimated 400,000 HIV-infected 
persons worldwide each year (1). Nonetheless, it is poorly understood specifically how HIV-
associated immunosuppression affects physiologic adaptations of the pathogen MTB. 
Enhanced understanding of this interaction is crucial because the phenotypic state of MTB 
alters antibiotic effectiveness (30, 41, 46-48) and may affect transmission fitness (49-51). 
HIV infection has pervasive effects on human immunity – ranging from altered 
cytokine and chemokine expression to changes in macrophage polarization to T cell 
dysfunction and depletion – leading to clinical, radiographic and histopathologic 
presentations of TB unlike those observed in immunocompetent hosts (43). Formation of 
granulomas – the hallmark human response to TB – is impaired. Unlike the finely-organized 
granuloma architecture of immunocompetent persons that displays a spatially-modulated 
gradient of T-cell and macrophage phenotypes, (138-140) patients with advanced HIV 
develop disorganized, poorly-contained collections of polymorphonuclear cells and 
eosinophils with a paucity of mononuclear, epithelioid or giant cells (141-145).  
MTB is exquisitely adapted to human immunity, dynamically adjusting its 
physiologic state to tolerate immune responses and diverse tissue micro-environmental 
conditions (38, 44, 45). In vivo microenvironments have variable pH, nutrient availability and 
oxygen tension. Hypoxia is encountered in the necrotic center of well-organized granulomas 





lesions like those formed by HIV-infected patients are not hypoxic (146-149). In response to 
conditions that limit aerobic respiration (hypoxia, carbon monoxide or nitric oxide (NO)), 
MTB induces up-regulation of the DosR regulon, (150) a set of genes that is essential for 
survival and virulence in well-formed hypoxic granulomas (146). DosR proteins additionally 
appear to modulate adaptive immunity, eliciting T cell responses (151) that enhance host 
granuloma formation (146).  
Pathogen-targeted gene expression profiling may provide a molecular snapshot of 
dynamic host-pathogen interactions (152-155) but has not been used to probe MTB 
adaptation to the altered immune milieu of HIV-infected human patients. Understanding 
bacterial phenotypes in human patients is important because the physiologic state of MTB in 
humans differs from phenotypes observed in vitro and in murine models (38-40, 156).  
We therefore compared MTB transcriptional adaptation to HIV-infected and 
uninfected hosts in the sputa of patients with untreated active pulmonary TB. After a pilot 
study in the Gambia revealed that MTB in HIV-infected patients had decreased expression of 
DosR regulon genes, we confirmed this result in a larger number of Ugandan patients. To 
elucidate alterations in human immunity that drive this adaptation, we queried a panel of 
human genes associated with granuloma formation and macrophage polarization.    
Methods 
Enrollment and specimen collection 
Adults with sputum acid-fast bacillus positive pulmonary TB were enrolled prior to 
antibiotic treatment at the Medical Research Council TB Diagnostic Laboratories, Fajara, 
The Gambia and Mulago National Referral Hospital in Kampala, Uganda. Using methods 





minutes in guanidine thiocyanate solution.  Sputa were needle-sheared, centrifuged at 
9000xg, and stored in Trizol at -80°C. All patients were offered HIV testing. Chest 
radiographs were evaluated for cavitation using a standardized protocol. Institutional review 
boards in The Gambia, Uganda and the US approved the study. All patients provided written 
informed consent.   
Laboratory analysis 
We selected only samples with both known HIV status and lineage 4 (EuroAmerican) 
spoligotype (to limit potential confounding due to lineage differences). Total RNA was 
extracted using a phenol/chloroform protocol described elsewhere (156). Quality assessment 
using a test panel targeting 24 MTB transcripts led to exclusion of a small number of 
samples. Gene expression profiling was performed for a random selection of eligible 
specimens in the pilot experiment (The Gambia) and all eligible specimens in Uganda. Our 
MTB expression profiling method is detailed elsewhere (156). Briefly, after first strand 
cDNA synthesis, cDNA underwent controlled multiplex amplification using Mtb-specific 
flanking primers.  2,179 Mtb transcripts were quantified via multiplex qRT-PCR with a 
LightCycler 480 (Roche, Indianapolis, IN) using TaqMan primers. 
To elucidate immunologic alterations that may drive differential MTB adaptation 
among HIV-infected patients, we also assayed a limited panel of human genes (n=234) 
selected because of their association with granuloma formation or macrophage polarization. 
Details of TaqMan primers are available at 
http://genes.stanford.edu/oli/genes.php?organism=h. Measurement of human gene expression 
was possible only in Ugandan samples; samples from the pilot experiment in The Gambia 






mRNA expression data were normalized using a median normalization method 
validated for this purpose (113).  We identified altered gene expression in HIV-infected 
versus uninfected hosts via t-tests with Benjamini-Hochberg multiple testing correction using 
a false discovery rate of 0.05.  We summarized the proportion of genes in previously 
described functional categories (156) with significantly increased or decreased expression 
with an unadjusted p-value <0.05, using a modified one-way Fisher’s exact test to identify 
enriched functional categories (p-value threshold <0.05). Analysis used the R statistical suite, 
version 3.0.1 except as noted in Supplement.  MIAME-compliant data are available at 
http://www.tbdb.org/rtpcrData.shtml.  
Results 
Enrollment and clinical characteristics 
In a pilot study, we assayed MTB gene expression in the sputum of 19 Gambian 
adults with drug-susceptible, sputum acid-fast bacillus smear-positive, culture-positive 
pulmonary TB. Four were HIV-infected. Thereafter, we enrolled 63 adults with sputum acid-
fast bacillus smear- or Gene Xpert-positive, culture-positive pulmonary TB in Uganda, 29 of 
whom were HIV-infected. Among HIV-infected Ugandan patients, median CD4 count was 
37 (Interquartile range 14-80) (Table 1). None were receiving highly active antiretroviral 
therapy at the time of TB diagnosis. Among Ugandans, radiographic cavitation was 
significantly less common among HIV-infected patients (n=13, 48%) than among HIV-






Decreased expression of MTB DosR regulon genes in HIV-infected patients 
Comparison of MTB expression between HIV-infected and uninfected patients in the 
Gambia, showed 447 (20.5%) genes had a p-value <0.05, considerably more than expected 
by chance alone. When repeated in Uganda, 344 (15.8%) genes had p-value <0.05. 
Enrichment analysis of functional gene categories (Table S1) in genes with p-value 
<0.05 showed that MTB expression of DosR regulon genes was significantly lower among 
HIV-infected patients than among HIV-uninfected patients (BH-adjusted p<0.0001 in the 
Gambia; p=0.0001 in Uganda). In the Gambia, 32 of 48 DosR regulon genes had 
significantly lower expression (p<0.05) among HIV-infected patients (Figure 1a-b); no DosR 
genes had significantly increased expression in HIV.  In Uganda, 20 DosR regulon genes had 
significantly lower expression among HIV-infected patients; one DosR gene (hypothetical 
protein Rv2628) had increased expression in HIV.  Expression of sentinel DosR genes was 
down-regulated among HIV-infected patients, including tgs1 (5.4-fold in the Gambia, 1.9-
fold in Uganda) , dosR (3.9-fold in the Gambia, 2.2-fold in Uganda), dosS (3.1-fold in the 
Gambia, 1.3-fold in Uganda) and hspX (acr) (2.0-fold in the Gamiba, 2.1-fold in Uganda). In 
both the Gambia and Uganda, expression of the DosR regulon was the dominant change; no 
other gene categories changed unambiguously.  
Host transcriptome indicates altered immune milieu in HIV 
Expression of human genes associated with granuloma formation and macrophage 
polarization were profoundly altered among HIV-infected patients (Figure 2). Of 234 genes 
assayed, 87 (37.2%) had a p-value <0.05 (Table Sx); 60 remained significant after adjustment 
for multiple comparisons. Relative to HIV-uninfected patients, HIV-infected patients had 





interferon regulatory factor 1 (IRF1) (1.8-fold, BH-adjusted p-value 0.02).  HIV-infected 
patients had higher expression of interleukin-4 (IL4) (4.0-fold, BH-adjusted p-value=0.03), 
interleukin-10 (2.7-fold, BH-adjusted p-value=0.002) and arginase 1 (ARG1) (3.0-fold, BH-
adjusted p-value=0.009). Expression of tumor necrosis factor alpha (TNF-α) and inducible 
nitric oxide synthase (NOS2) was unchanged (BH-adjusted p-values 0.6 and 0.2, 
respectively).  
Discussion 
HIV transforms the interaction between MTB and its human host. In two 
geographically-distinct human populations, we found that MTB in HIV-infected patients had 
decreased expression of the DosR regulon, a crucial metabolic switch with 
immunomodulatory effects. Down-regulation of DosR expression among HIV-infected 
patients may be a direct result of arginase-driven decreased macrophage NO production or an 
indirect result of decreased hypoxic stress in poorly formed granulomas. This analysis 
provides a novel perspective on the complex interplay between HIV-associated immune 
impairment, altered tissue microenvironments and bacterial physiologic state. 
The DosR regulon is genetic program that directs metabolic adaptation to conditions 
that inhibit aerobic respiration and cause reductive stress in a pathogen that is an obligate 
aerobe (150, 157). In immunocompetent hosts that form well-organized hypoxic granulomas, 
DosR is necessary to sustain persistent infection beyond the onset of adaptive immunity 
(146). Conversely, DosR is not required in animal models that form poorly-organized, non-
hypoxic lesions similar to those observed in HIV-infected patients (147, 158).  
Decreased induction of the DosR regulon may be due to several interacting 





samples suggests altered macrophage polarization that may decrease NO production. 
Consistent with previous studies (159-162), HIV-infected TB patients in this study had 
decreased expression of interferon-γ  (IFN-γ), a principal mediator of macrophage activation 
in TB (163) and increased expression of interleukin-10 (IL-10), a Th2 cytokine that induces 
alternative (anti-inflammatory) macrophage polarization and enhances MTB survival (160, 
164, 165). Furthermore, HIV-infected patients had a 3-fold increase in expression of Arg1, 
characteristic of pro-healing, anti-inflammatory macrophages (139). Arg1 competes with 
NOS2 for L-arginine, down-regulating macrophage NO production and increasing 
susceptibility of mice to MTB (165, 166).   
Dysregulation of granuloma morphology may decrease hypoxic stress, (146-149) 
thereby decreasing MTB requirement for DosR. HIV-infected subjects in this study had 
profound depletion of CD4 lymphocytes, a central component of well-organized granulomas 
(144, 167) and had a Th2-biased cytokine environment. In addition to direct effects on 
macrophage polarization cited above, IFN-γ is critical to granuloma formation. Conversely, 
IL-10 expression inhibits formation of mature granulomas (168) and Arg1 limits T-cell 
proliferation, independent of its effect on NO (138).  
Finally, MTB encounters profoundly hypoxic conditions within macrophages (51).  If 
the immune dysregulation associated with HIV increases the proportion of MTB that is extra- 
rather than intracellular, the result would be decreased hypoxic stress and decreased DosR 
expression. These putative mechanisms leading to decreased DosR expression in HIV may 






The interaction between host microenvironments and bacterial physiology is not 
necessarily one-sided. A number of DosR regulon proteins have strong T-cell and IFN-γ 
inducing capacity (151, 169) and appear to enhance granuloma formation (146, 158). 
Consistent with this hypothesis, DosR mutants cause less tissue pathology in mice relative to 
wild-type MTB despite a similar bacillary burden (170). This suggests that down-regulation 
of the DosR regulon may be not only a consequence but also a cause of altered host 
responses in HIV/TB co-infected patients.       
The MTB transcriptional alterations we identified among HIV-infected subjects are 
important because the pathogen’s phenotypic state influences antibiotic effectiveness both in 
vitro (41, 47, 48)  and in vivo (171). For example, comparison of C3H3b/FeJ mice that form 
human-like caseating hypoxic granulomas with Balb/c mice that form non-hypoxic lesions 
(172) showed different responses to clofazamine (171). Future research is needed to 
understand specifically how the altered tissue microenvironments that result from HIV-
associated immune dysregulation affect MTB response to antibiotics in humans.  
This study has several limitations. Different MTB strains could have different gene 
expression responses. We alleviated, but did not entirely eliminate, this potential confounder 
by restricting our analysis to MTB of EuroAmerican lineage. Second, since our patients did 
not undergo lung biopsy, we could not directly assess granuloma organization and tissue 
oxygen tension. However, previous reports have described a strong and consistent impact of 
HIV on granuloma morphology (141-145) and disorganized uncontained granulomas are 
shown in animals to be non-hypoxic (146-149). Since HIV-infected subjects in this study had 







MTB differentially adapts its physiologic state to the HIV-infected host.  Likely 
driven by diminished NO stress from alternatively activated macrophages and diminished 
hypoxic stress in disorganized granulomas, MTB in HIV-infected patients displayed 
decreased expression of DosR, a bacterial response to hypoxia with immunomodulatory 
effects.  These observations identify novel connections between host immunity, host tissue 
micro-environments and bacterial phenoptypes.  Further investigation of determinants of 
MTB phenotypes during human infection is important because bacterial physiologic state 






Table 1. Demographic and clinical characteristics of TB patients in The Gambia (pilot study) 
and Uganda that underwent pathogen-targeted gene expression profiling. 
a CD4 T cell count unavailable in pilot experiment in The Gambia. 
b Chest radiographs missing for one HIV-infected and three HIV-uninfected subjects. 
c Chest radiographs missing for two HIV-infected and six HIV-uninfected subjects. 
 
  
Characteristic HIV-infect ed HIV-uninfected p-value 
Age (median, IQR)    
The Gambia 36 (28-44) 25 (21-32) 0.4 
Uganda 30 (27-38) 26 (22-32) 0.1 
Female (n, %)    
The Gambia 3 (75%) 1 (7%) 0.02 
Uganda 13 (45%) 11 (32%) 0.5 
CD4+ T-cell count (median, IQR)a    
Uganda 37 (14-80) - - 
Radiographic cavitation (n, %)    
The Gambia  b 1 (33%) 8 (67%) 0.7 
Uganda c 13 (48%) 25 (89%) 0.003 
Light microscopy results (n, %)    
The Gambia    
Negative -   
Scanty / 1+ - 1 (7%)  
2+ 1 (25%) 4 (27%)  
3+ 3 (75%) 10 (67%)  
Uganda    
Negative 1 (7%) -  
Scanty / 1+ 5 (17%) 5 (15%)  
2+ 11 (38%) 9 (27)  






Figure 1.  Expression of MTB DosR regulon in the sputum of HIV-infected versus HIV-
uninfected TB patients in the Gambia (A) and Uganda (B), log2 scale.  Red indicates 









Figure 2.  Differential expression of human genes associated with granuloma formation and 
macrophage polarization in HIV-infected versus uninfected TB patients with hypothesized 
consequences.  Red indicates significantly decreased and green indicates significantly 
increased expression in HIV-infected samples.  Mean fold-change in HIV-infected relative to 
uninfected samples is shown in parentheses.  The observed decreased expression of key Th1 
and increased expression of Th2 cytokines in HIV may contribute to impaired granuloma 
formation, diminishing hypoxic stress. Increased expression of Arg1 in HIV may compete 
with iNOS for L-arginine, decreasing NO production.  Arg1 additionally inhibits granuloma 
formation. A number of DosR regulon proteins strongly induce T-cell and IFN-γ responses, 
enhancing granuloma formation. Decreased expression of the DosR regulon is therefore 











These projects presented in this dissertation have developed novel practical 
approaches for using data science to advance public health interventions in TB.  The 
components address several major public health challenges.   
The first project – an analysis of LTBI reactivation risk among immigrants – 
addresses a critical problem.  A centerpiece of domestic TB control is a strategic plan for 
“elimination” of TB within the US, defined as less than 1 case per million persons per year 
(173).  Substantial progress has been made in recent decades.  For example, the US rate of 
TB diagnosis declined 71% from 1990 to 2014, from 10.3 to 3 per 100,000 (5).  However, 
these gains were made primarily among US-born persons.  The foreign-born share of TB has 
risen continuously.  During these 25 years, the percentage of all TB diagnosed among 
foreign-born persons rose from 26% to 67%.  TB among immigrants and the foreign-born is 
therefore considered the central obstacle to TB elimination in the US.   
TB in the foreign born is a particularly challenging problem because transmission of 
active TB has been largely interrupted within the US (2, 3).  Most TB cases within US occur 
as a result of exposures and infections acquired prior to US arrival, (4) meaning preventive 
treatment of LTBI is the only effective prevention strategy.  In 2013, approximately 41.3 
million persons in the US were foreign-born (174). The prevalence of LTBI is approximately 
10 time higher among foreign-born persons than among than US-born persons (3).  To 
effectively target LTBI treatment towards persons at highest risk of developing TB, it is 





The first project in this dissertation addressed this challenge using a novel study 
design to estimate TB risk among immigrants over time.  We found that it is possible to link 
overseas pre-immigration screening records with domestic TB case reports, creating a 
retrospective longitudinal cohort.  Analysis of this dataset challenges the conventional 
wisdom that risk of LTBI reactivation is highest in the immediate post-arrival period.   
Current guidelines appear to be based on ecological fallacy.   
Our finding that TB risk in immigrants with normal pre-immigration chest 
radiographs is stable over time has important implications for US TB control strategies.  In 
order to maximize public health benefit, current guidelines emphasize targeting screening 
and preventive treatment to the populations at highest risk for TB.  Our data suggest that 
newly arrived immigrants with normal chest radiographs do not have uniquely high rates of 
TB.  Risk among newly-arrived immigrants is in fact similar to TB risk among immigrants 
who have been in the US longer.  It suggests that targeted testing and preventive treatment 
should be extended to all foreign-born persons with evidence of LTBI, regardless of duration 
in the US.  
This makes the challenge of TB prevention in the US even more challenging than 
previously anticipated.  Fifteen years ago in a perspective entitled “Tide pools: what will be 
left after the tide has turned?,” Paula Fujiwara predicted the challenge of diminishing returns 
of TB prevention efforts as TB incidence declined (175).  Our findings are consistent this 
prediction.  As the tide of TB in the US has receded to historically low levels, the cost of 
further TB prevention has grown.  Since the individual risk for TB is lower in the general 
population of foreign-born persons than previously (erroneously) assumed in the population 





This has important implications for the cost-effectiveness of TB prevention.  Our findings are 
also important for models that estimate prevention benefits of LTBI treatment and estimate 
the feasibility of TB elimination in the US.  
Finally, the methodology developed  in this project for performing transnational 
linkage of immigration screening data and using results for surveillance and program 
evaluation has been published (176). Our novel method is additionally potentially useful for 
case ascertainment in a clinical trial. This method has enabled submission of an R34 to plan 
an LTBI screening and treatment trial based at overseas pre-immigration screening sites. Our 
linkage method enables subjects to be followed electronically for development of TB after 
US arrival.    
The second project in this dissertation also addresses a topic of critical importance in 
TB control: accurate early detection of active TB.   Current diagnostic tests have inadequate 
sensitivity, meaning missed diagnoses are common (11).  The result is continued disease 
progression for individual patients and continuing TB transmission within the community.  
Therefore, development of novel assays for TB is a leading World Health Organization 
priority (12). 
Our project tested a promising approach to diagnosis – classification based on blood 
transcriptional profiles – in a population that has not previously been evaluated.  Specifically, 
we evaluated a group of patients with ethnic heritage and co-morbidities typical of those 
observed among US TB patients.  In addition to development of novel transcriptional 
signatures in this population, we systematically evaluated the generalizability to other 





This study provided important insight into blood transcriptional classifiers for TB and 
also has more general implications for biomarker development generally.  Our analysis was 
able to identify transcriptional patterns that accurately distinguished active TB from either 
LTBI or pneumonia within our patient cohort.  However, we found that the reference group 
used in classifier development was critically important, both in terms of the transcripts 
included in the classifier and in terms of the practical usefulness of the classifier.  For 
example, a classifier established by comparing TB with latent TB was unable to distinguish 
TB from pneumonia.  Similarly, our classifier developed by comparing TB with pneumonia 
was less accurate at classifying TB when tested among patients with TB or cancer.  And a 
classifier developed by other investigators based on comparison of TB and cancer was less 
accurate for detection of TB when tested among patients with TB or pneumonia.  These 
results suggest that classifiers developed via comparison with a single disease reference may 
be excessively specific to that comparison.  Clinically, the practical challenge is that a 
practical assay must distinguish active TB from a diverse spectrum of diseases, including 
pneumonia, cancer and a number of additional conditions.  Therefore, while our results are 
encouraging because they show TB can be distinguished from pneumonia based on the blood 
transcriptome, our analysis also points to the need for further cross-cohort and cross-study 
comparison to identify classifiers that are robust and generalizable enough to be used as “real 
world” practical assays for TB.    
The third project in this dissertation used pathogen-targeted transcriptional profiling 
to evaluate transcriptional characteristics of the drug-tolerant MTB population that survives 
prolonged drug exposure in human sputum.  The drug-tolerant persister MTB phenotypes 





demand prolonged drug exposure to eradicate and are considered the root cause of treatment 
failure and relapse. Our novel approach to characterizing changes in the physiological state 
bacterial population during treatment of human TB provided new perspective on the 
physiologic alterations that enable drug tolerance.  
This preliminary proof-of-concept study leads to new questions.  Can this method of 
pathogen-targeted transcriptional profiling in sputum be used as a pharmacodynamic measure 
of drug impact?  Could it be used to evaluate novel drug regimens?  Would different drug 
regimens result in different physiologic adaptations by the bacterial population (as indicated 
by different transcriptional patterns)?   Additionally, would MTB transcriptional patterns be 
different in patients who are bound to relapse compared with patients who are successfully 
durably cured?  Could MTB transcriptional patterns serve as surrogate markers for 
subsequent treatment failure or relapse?  Lack of early surrogate markers predictive of 
relapse is a major challenge for TB drug development. Better surrogate markers – based on 
molecular measures of pathogen physiology rather than culturability – would accelerate the 
drug development pipeline by reducing the size, cost and time duration of clinical trials. 
These questions would need to be evaluated in a large-scale drug trial.   
The fourth and final project in this dissertation evaluated the impact of host immunity 
on the MTB transcriptome prior to treatment by comparing MTB isolated from HIV-infected 
and HIV-uninfected patients.  It revealed that host immune milieu has an important impact 
on the physiologic state of the MTB population.  Specifically, HIV-induced immune 
derangements were associated with decreased expression of genes of DosR regulon, a critical 





 This important and novel observation should inspire additional lines of investigation.  
Binary classification of immune responses as HIV-infected or HIV-uninfected is a crude 
measure of the immune responses MTB encounters in vivo. In reality, there may be a range 
of immune responses among HIV-infected patients or among HIV-uninfected patients.  With 
more nuanced phenotyping of human immune responses, it is possible that future analyses 
will identify important interactions between MTB and host immunity.     
In the aggregate, these four projects harnessed novel forms of large-scale 
administrative or biological data to address public health challenges in TB control.  The 
continuing challenge will be translation from analysis to insights that will lead to practical 
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SUPPLEMENTAL METHODS AND RESULTS FOR CHAPTER 3 
Blood transcriptional biomarkers for active TB among US patients: 
Case-control study with systematic cross-classifier comparison 
ePAT Study Sites 
Consecutive subjects meeting criteria for TB and LTBI groups were enrolled in 
outpatient TB control programs in Colorado [Denver Metro Tuberculosis Clinic, Denver] and 
Texas [Fairpark Clinic (Harlingen), Brownsville Clinic (Brownsville) of Cameron County 
Health Department; Edinburg Pulmonary Clinic (Edinburg) of Hidalgo County Health 
Department; San Antonio Metropolitan Health District (San Antonio); Audie L Murphy 
Veterans Administration Medical Center during 2010-2011.  Consecutive subjects meeting 
the community-acquired pneumonia case definition were enrolled in the Denver Health 
Medical Center Emergency Department. 
Classifier development and evaluation 
Cross-validation for model tuning 
ePAT transcriptional classifiers were support vector machines (SVM). For each 
classifier type, 20 iterations of 6-fold cross-validation were performed using training set 
samples to select model parameters. The minimal number of transcripts (features) required 
was additionally treated as a parameter in model selection.   
Minimal number of features for each classifier  
As required for unbiased cross validation,  feature selection was repeated de novo 
with each fold of cross-validation (177). For each fold, the predictive value of each transcript 





RFE)(98).  SVM-RFE began by training an SVM classifier [e1071 package, version 1.6.3 
using default settings: cost = 1, linear kernel] using all 21,734 probesets. The weight of each 
transcript’s contribution to the SVM classifier was ranked and the least-predictive 20% of 
transcripts were removed. A new SVM was trained using remaining transcripts and the 
process was iterated until all transcripts were removed. The result was a rank list of all 
transcripts in order of predictive value for each fold.
 
We identified the minimal number of transcripts required for each classifier as 
follows. Multiple SVM models including between the top 5 and the top 200 transcripts from 
the SVM-RFE rank lists were evaluated. The misclassification error in 20 iterations of 6-fold 
cross-validation was quantified.  The figure below illustrates the misclassification rate 
according to the number of transcripts included in the classifier for the type 1 (TB vs 
pneumonia), type 2 (TB vs LTBI), and type 3 (TB vs LTBI or pneumonia) classifiers.  We 
used an established backwards selection approach to identify the point at which removing 
additional transcripts substantially worsened classification (99, 100). Starting with the largest 
classifier (200 transcripts), we evaluated successively smaller classifiers until we identified 
the first point at which elimination of a single transcript resulted in a misclassification rate 
greater than the misclassification rate of the preceding classifier plus one standard error.  
Based on this analysis, the TB vs pneumonia classifier included 47, the TB vs LTBI included 
51 transcripts, and the TB versus LTBI or pneumonia included 119. Importantly, this process 
identified the number of transcripts that would be included in each classifier. The specific 







Figure A1.  Misclassification rate in cross-validation according to number of transcripts 
included in classifier.  Results are shown for three classifier types:  (A) TB vs. pneumonia, 
(B) TB vs. LTBI and (C) TB vs. pneumonia or LTBI.  Points represent the proportion of 
samples misclassified in classifiers including a given number of transcripts.  Dotted bands 
represent one standard error around the misclassification rate.  The vertical dotted line 
indicates the point at which elimination of a single transcript resulted in a misclassification 
rate that exceeded the misclassification rate of the next largest classifier plus one standard 
error.    
Selection of SVM parameters 
Model parameters were optimized in the training set using the tune.svm function in 
the R package e1071, version 1.6.2.  This function performs a grid search over a range of 





classification threshold was adjusted such that sensitivity and specificity were approximately 
equal in cross-validation. Final parameters are listed below. 
 
Estimation of accuracy in training set 
After selection of model parameters, classification accuracy in the training set was 
estimated as follows.  Six-fold cross-validation was repeated 20 times and the mean 
sensitivity and specificity were calculated. After confirming that sensitivity and specificity 
estimates from 20 iterations of cross-validation were approximately normally distributed, 
95% two-sided  t19, 0.975  confidence intervals were estimated. Receiver Operating 
Characteristic (ROC) curves and Area Under the Curve (AUC) estimates were generated for 
Training Set Samples using the cvAUC package, version 1.1.0 for each of the 20 iterations 
(178).  Thus, 20 cross-validated ROCs and the corresponding AUCs were produced to assess 
the overall accuracy. The mean and standard error of the 20 cross-validated AUCs were 
calculated, and the lower and upper 95% confidence limits were determined by subtracting 
and adding, respectively,  t19, 0.975  standard errors from the mean AUC. 
Final transcript sets for each classifier 
The number of transcripts to be included in each classifier was identified through 
cross-validation as described above. To identify the specific transcripts that would be 
included in each classifier, SVM-RFE was implemented with all training set samples without 
cross-validation.  The top 47, 51 and 119 transcripts were used for the ePAT type 1, 2, and 3 
classifiers, respectively.      
Final SVM parameters 
 Weighting Kernel Cost 
Type 1: TB vs pneumonia None Linear 0.005 
Type 2: TB vs LTBI None Linear 0.005 





Evaluation in ePAT test set 
The three transcriptional classifiers developed above were used to predict the disease 
state of test set samples without modification of model parameters. Confidence intervals for 
sensitivity and specificity were estimated using the exact binomial methods implemented in 
epiR, version0.9-62.   ROC curves were produced and AUC calculated using the pROC 
package in R (version 1.7.3).   
External validation of ePAT classifiers 
To validate our classifiers in an independent external population, we utilized 
publically-available transcriptional data available on NCBI Gene Expression Omnibus 
[GSE37250] from Kaforou, (19) the largest existing whole blood transcriptional classifier 
study of adults with TB.  To accommodate differences in microarray platform, we converted 
our Affymetrix HuGene ST 1.1 transcript cluster identifiers for transcripts in ePAT 
classifiers to Illumina HumanHT12v4 identifiers.  For the transcript identifiers currently 
annotated with a gene symbol, we identified Illumina identifiers with matching gene 
symbols. Where the original Affymetrix gene symbol did not match current Illumina gene 
symbols, we manually searched NCBI and other databases for synonymous gene symbols 
that matched.   
Following platform conversion, we tested ePAT classifiers in the Kaforou dataset 
with 6-fold cross-validation using an SVM with the final parameters described above. The 
ePAT type 1 classifier was tested in Kaforou subjects with TB or other diseases. The ePAT 
type 2 classifier was tested in Kaforou subjects with TB or LTBI.  The ePAT type 3 classifier 
was tested in Kaforou subjects with TB or LTBI or other diseases.  ePAT classifiers were 





repeated 20 times and sensitivity, specificity and AUC were estimated using methods 
identical to those described for the training set above after assessing normality  
Systematic review of published literature 
Review methods 
Selection Criteria: We included all studies which developed expression classifiers 
distinguishing active pulmonary TB from other conditions based on whole transcriptome 
microarray analysis of human whole blood using SML algorithms.  We excluded the 
following types of studies: (1) studies which primarily evaluated expression change in 
response to TB treatment , (2) studies of transcriptional differences between patients with 
first-time and recurrent TB,  (3) studies focused on non-tuberculosis mycobacteria or extra-
pulmonary tuberculosis, (4) studies of specimens other than whole blood, (5) abstracts, case 
reports, editorials, commentaries, and reviews.  We maintained a list of excluded studies and 
the reasons for their exclusion.    
Two reviewers independently screened the accumulated citations for relevance and 
reviewed full-text articles using pre-specified eligibility criteria; they resolved disagreements 










TB[Title]) AND blood[Title/Abstract]) AND 
("2005/01/01"[PDAT] : "3000"[PDAT])) 
NOT pbmc[Title/Abstract]) AND 
expression[Title/Abstract]) NOT 
("vaccination"[MeSH Terms] OR 
"vaccination"[All Fields])) NOT 
mononuclear[All Fields]) AND 
"humans"[MeSH Terms] 
a
 For papers published from January 1, 2005 to the present. 
b
 Results were further refined in EndNote, searching for RNA Microarray Studies among 
imported PDFs. 
 
Evaluation of previously published classifiers 
We evaluated whether previously published transcriptional classifiers identified 
during systematic literature review accurately classify ePAT samples.  First, we converted 
transcript identifiers from the original microarray platforms to Affymetrix HuGene ST 1.1 
identifiers.  Second, we used the same classification methods described in previous 
publications to test the classification accuracy of each previously published classifier in 
ePAT data.  These steps are described in detail below.  
Transcript conversion to Affymetrix identifiers 
We abstracted lists of transcript identifiers included in previously published 
classifiers from the original manuscripts and converted these identifiers to Affymetrix 
HuGene ST 1.1 transcript cluster IDs.  For the transcript identifiers currently annotated with 
a gene symbol, we identified Affymetrix IDs with matching gene symbols.  Where the 
original gene symbol did not match current Affymetrix gene symbols, we manually searched 
NCBI and other databases for synonymous gene symbols that matched.      
Most published classifiers included a number of transcript identifiers that lack current 





subsequently been demonstrated to exist. Since they do not correspond to any known 
transcript, these non-annotated identifiers could not be converted to Affymetrix IDs.  
Classification using Kaforou classifiers 
We evaluated the classification accuracy of the Kaforou (19) classifiers in ePAT 
training and test sets. The Kaforou Type 1 TB vs other diseases classifier included 26 
transcript identifiers after conversion to Affymetrix and was tested in ePAT TB and 
pneumonia samples. The Kaforou Type 2 TB vs LTBI classifier included 42 transcript 
identifiers after conversion to Affymetrix and was tested in ePAT TB and LTBI samples. The 
Kaforou Type 3 TB vs LTBI or other diseases classifier included 44 transcript identifiers 
after conversion to Affymetrix and was tested in ePAT TB and LTBI or pneumonia samples.  
The Disease Risk Score (DRS) developed and implemented by Kaforou was used for 
classification. Sensitivity, specificity and AUC were estimated based on 20 iterations of 6-
fold cross-validation using methods identical to those described for the training set.   
Classification using Bloom classifier 
We evaluated the classification accuracy of the Bloom (13) classifier in our training 
and test sets using only the 117 transcript identifiers converted from the Bloom list.  A linear 
SVM (the same method used by Bloom) was implemented with cost = 0.01 and 2:1 
weighting to adjust for imbalanced groups. Sensitivity, specificity and AUC were estimated 
based on 20 iterations of 6-fold cross-validation using methods identical to those described 
for the training set. 
Classification using Berry classifiers 
We evaluated the classification accuracy of the Berry (15) classifiers in ePAT training 





identifiers after conversion to Affymetrix and was tested in ePAT TB and pneumonia 
samples. The Berry Type 2 TB vs LTBI classifier included 80 transcript identifiers after 
conversion to Affymetrix and was tested in ePAT TB and LTBI samples. K-nearest 
neighbors (the same method used by Berry) was implemented with K=3 using the class 
package in R. Sensitivity, specificity and AUC were estimated based on 20 iterations of 6-
fold cross-validation using methods identical to those described for the training set.   
Classification using Maertzdorf classifier 
We evaluated the classification accuracy of the Maertzdorf (16) classifier in our 
training and test sets using only the 70 transcript identifiers converted from the Maertzdorf 
list.  Random forest (the same method used by Maertzdorf) was implemented using the 
randomForest package (version 4.6-10) in R with ntree=1000, mtry =5.  To adjust imbalance 
in group sizes, we down-sampled the larger group during training of the random forest model 
as recommended by random forest developers (179). Sensitivity, specificity and AUC were 
estimated based on 20 iterations of 6-fold cross-validation using methods identical to those 











SUPPLEMENTAL METHODS AND RESULTS FOR CHAPTER 4 
Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis  
during human tuberculosis 
Enrolment and clinical evaluation 
From a consecutive random sample of adults (age ≥ 18 years) with cough of at least 2 
weeks admitted to Mulago National Referral Hospital and enrolled in a parent TB diagnostic 
study, (180) we recruited patients with sputum AFB smear-positive, culture-positive 
pulmonary TB.  We excluded from the eligible population any patient who was unable to 
expectorate sputum, already receiving anti-TB therapy, infected with drug-resistant MTB, 
too ill to walk, severely anemic, residing more than 20 kilometers from the study site, or 
lacking a treatment supporter.  (Figure B1, Enrollment flow diagram)  Resource constraints 
prevented us from performing gene expression profiling for all enrolled patients.  Therefore, 
of patients who were enrolled and provided specimens, 17 were randomly selected with 






Figure B1.  Enrolment flow diagram    
At enrollment, we collected demographic and clinical information using a 
standardized questionnaire. All patients underwent HIV antibody testing and blood CD4+ T-
lymphocyte measurement if HIV-seropositive. All patients provided one specimen for 
molecular testing on direct sputum (GeneXpert MTB/RIF, Cepheid Diagnostics, Sunnyvale, 
CA), and two specimens for smear microscopy and mycobacterial culture.  Adherence to TB 
therapy was assessed at each follow-up visit.  All patients were followed for up to 2 years 
after their last treatment visit to adjudicate treatment outcomes. 
Human subjects approval 
Institutional Review Boards at Makerere University, Mulago Hospital, the Uganda National 
Council for Science and Technology, the University of California San Francisco, and the 








Extraction of total RNA 
Total RNA was extracted using a glass matrix tube for cell lysis (Lysing Matrix B, Q 
Biogene) in a FastPrep FP120 instrument (Bio 101, Thermo Savant) with a speed setting of 6 
for 3 x 30 seconds, with cooling on ice for 1 minute in between. After processing, chloroform 
was added twice, followed by separation of the aqueous and organic layers. The aqueous 
phase containing the RNA was removed to a fresh tube and the RNA was precipitated 
overnight at -20C after addition of glycoblue (Ambion), 0.1 volume of 5 M ammonium 
acetate, and an equal volume of isopropanol were added. The resulting RNA pellet was 
cleaned by three rounds of the RNeasy® mini column system, interspersed with off-column 
DNAse treatments (Promega RQ1 DNAse).  
Extraction of genomic DNA 
Genomic DNA was extracted along with total RNA for each sample.  The interphase 
containing the DNA and organic layers were removed to a fresh tube and a volume of 
guanidine thiocyanate-based buffer was added (equivalent to 0.5 volume of Trizol used in the 
extraction ).  Samples were mixed for 10 minutes. then centrifuged at 12,000 x g for 30 
minutes. at room temperature.  The aqueous phase now containing the DNA was removed to 
a fresh tube.  Glycoblue and 0.4 volume of isopronal were added.  Samples were mixed by 
inversion and precipated for 10 minuntes. at room temperature.  The resulting DNA pellet 
was washed twice with 70% ethanol and resuspended in nuclease-free water.  
qRT-PCR expression profiling 
Multiplex qRT-PCR was used to selectively amplify and quantify expression of 





profiling low abundance MTB mRNA in a mixed sample (predominantly of human mRNA).  
Briefly, 2,411 MTB transcripts underwent controlled PCR pre-amplification using 
outflanking forward and reverse primers following first strand cDNA synthesis.   Following 
amplification, expression of these 2,411 MTB transcripts was quantified via 384-well format 
multiplex qRT-PCR with a LightCycler 480 (Roche, Basel, Switzerland). Sequences, design 
and validation details of PCR primer/probe sets can be found at 
http://genes.stanford.edu/technology.php and http://www.tbdb.org/rtpcrData.shtml. 
Statistical analysis 
Estimation of change in nucleic acid abundance 
We used the following measures of nucleic acid abundance. 
 mRNA – No single mRNA transcript or group of transcripts has been demonstrated to be 
consistently expressed in sputum during treatment.  Therefore, to obtain an aggregate 
measure of MTB mRNA abundance in each sample, we calculated the median cycle 
threshold (CT) value of the 100 most highly expressed transcripts ineach sample.  For 
each sample, we then quantified the percentage decrease in this value relative to the 
patient’s pre-treatment (day 0) value.   
 16S rRNA – ribosomal gene copy number (RGCN) in each sample was estimated relative 
to genomic standards (105 or 106 genomes H37Rv).  For each sample, RGCN was then 
transformed to a percentage decrease from pre-treatment RCGN. 
 DNA – genome equivalents (GE) in each sample were estimated relative to a genomic 
standard (104 genomes H37Rv).  For each sample, GE was then transformed to a 





To characterize average changes in relative abundance of MTB mRNA, 16S rRNA 
and DNA over time, we calculated geometric mean percentage changes from day 0 to days 2, 
4, 7, 14, 28 and 56. Geometric rather than arithmeic means were used because they are less 
sensitive to right skewness. A saturated linear mixed model was used to obtain 95% 
confidence intervals for the geometric means.  Models were estimating using Stata Version 
13.1 (Stata Corp, College Station, TX). 
Data normalization  
Because there are no validated endogenous cntrol (housekeeping) genes, we applied 
a minimum variance, data-driven normalization method described elsewhere (113) to adjust 
for the progressive decline in the sputum bacillary oad that occurs with ongoing treatment. 
This method is more robust to non-detected probes than other data-driven normalization 
methods such as quantile normalization, (113) enabli g normalization of samples with up to 
50% non-detected probes. Most samples from days 28 and 56 had very low nucleic acid 
abundance and >50% of probes were non-detectable; data from these time-points were 
therefore not normalized and were analyzed separately.    
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